lactic acid has been researched along with Diabetes Mellitus, Adult-Onset in 284 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Moreover, MET-associated lactic acidosis (MALA) needs to be considered and the incidence of MALA in patients with type 2 DM-TB coinfection remains unknown." | 9.27 | A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients. ( Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2018) |
| " However, if used in excessive doses for patients with kidney disease, it will be contraindicated with side effects such as lactic acidosis." | 9.22 | Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease. ( Rahman, F; Tuba, S, 2022) |
| "Twelve outpatients with type II diabetes mellitus and mild clinical signs and history of cardiac failure were studied to assess the effects of ibopamine on glucose and lipid metabolism." | 9.06 | Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study. ( Cicchetti, V; DiCarlo, A; Giannarelli, R; Marchetti, P; Navalesi, R; Sabino, F, 1990) |
| "Metformin-associated lactic acidosis (MALA) is a rare adverse effect that has significant morbidity and mortality." | 9.05 | Osmolar-gap in the setting of metformin-associated lactic acidosis: Case report and a literature review highlighting an apparently unusual association. ( Alamin, M; Elshafei, MN; Mohamed, MFH, 2020) |
| "Metformin-associated lactic acidosis (MALA) is a rare but potentially fatal condition that can easily be avoided." | 8.95 | [Metformin-associated lactic acidosis: an insufficiently recognised problem]. ( Bosch, FH; Kramers, C; Manders, M; van Luin, M, 2017) |
| " Metformin, however, is thought to increase the risk of lactic acidosis, and has been considered to be contraindicated in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age." | 8.86 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. ( Greyber, E; Pasternak, GA; Salpeter Posthumous, EE; Salpeter, SR, 2010) |
| " Metformin, however, is thought to increase the risk of lactic acidosis, and has been considered to be contraindicated in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age." | 8.86 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. ( Greyber, E; Pasternak, GA; Salpeter, EE; Salpeter, SR, 2010) |
| "Lactic acidosis is a disease in which lactic acid accumulates in the blood and causes acidosis in the patient." | 8.31 | Metformin-associated severe lactic acidosis combined with multi-organ insufficiency induced by infection with Aeromonas veronii: A case report. ( Wu, C; Xia, Y; Zhu, X, 2023) |
| "This study investigated the safe use of metformin in patients with (1) type 2 diabetes mellitus (T2DM) and heart failure on metformin, and (2) heart failure without T2DM and metformin naïve." | 8.31 | The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study. ( Carland, JE; Chowdhury, G; Day, RO; Graham, G; Greenfield, JR; Hayward, CS; Kumar, S; Kumarasinghe, G; Macdonald, P; Olsen, N; Stocker, SL, 2023) |
| "Metformin-associated lactic acidosis (MALA) is a widely documented adverse event of metformin." | 8.02 | The usefulness of measuring the anion gap in diagnosing metformin-associated lactic acidosis: a case series. ( Agra-Montava, I; Juanes-Borrego, A; Lozano-Polo, L; Mangues-Bafalluy, MA; Puig-Campmany, M; Ruiz-Ramos, J, 2021) |
| "Metformin-associated lactic acidosis (MALA) carries a high mortality rate." | 7.96 | Metformin-associated lactic acidosis: reinforcing learning points. ( Creagh, F; Goonoo, MS; Morris, R; Raithatha, A, 2020) |
| " We report three cases of prospectively identified laboratory confirmed metformin-associated lactic acidosis admitted to our intensive care unit." | 7.91 | Laboratory-Confirmed Metformin-Associated Lactic Acidosis ( Canavan, C; Coyle, N; Nasim, S; Nestor, C, 2019) |
| "To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3-5." | 7.91 | Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: is it significant? ( Guddattu, V; Mareddy, AS; Nagaraju, SP; Prabhu, RA; Rangaswamy, D, 2019) |
| "Metformin-associated lactic acidosis is a rare but serious complication of taking metformin." | 7.91 | Metformin-Associated Lactic Acidosis Presenting Like Acute Mesenteric Ischemia. ( Hastings, C; Johnson, K; Slaven, E; Zhang, QC, 2019) |
| "Pharmacokinetic data suggest that the risk of metformin-associated lactic acidosis (MALA) may be increased after Roux-en-Y gastric bypass (RYGB) surgery." | 7.88 | Risk of Metformin-Associated Lactic Acidosis (MALA) in Patients After Gastric Bypass Surgery. ( Aarts, EO; Aelfers, SCW; Berends, FJ; de Boer, H; Deden, LN; Janssen, IMC; van Borren, MMGJ, 2018) |
| "Metformin is renally excreted and has been associated with the development of lactic acidosis." | 7.85 | Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. ( Connelly, PJ; Donnelly, L; Lonergan, M; Pearson, ER; Soto-Pedre, E; Zhou, K, 2017) |
| " There was no difference in prevalence of hyperlactatemia and lactic acidosis between the patients with and without metformin use (18." | 7.85 | Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. ( Cha, BS; Han, E; Hwang, S; Kang, ES; Kang, HP; Lee, BW; Lee, EY; Lee, HC; Lee, SH; Lee, W; Lee, YH; Lee, YM, 2017) |
| "The role of metformin in lactic acidosis is regularly questioned." | 7.83 | Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. ( Altman, JJ; Boucaud-Maitre, D; Bouhanick, B; Doucet, J; Emmerich, J; Girardin, E; Kaloustian, E; Lassmann Vague, V; Porokhov, B; Ropers, J, 2016) |
| "To evaluate the strength of association between lactic acidosis (LA) and well-recognized risk factors for LA, particularly the weight of metformin." | 7.83 | Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University. ( Chanoine, S; Giai, J; Lepelley, M; Villier, C; Yahiaoui, N, 2016) |
| "We report a case of metformin-associated lactic acidosis (MALA) in the setting of normal renal function and review the relevant medical literature." | 7.83 | Metformin-Associated Lactic Acidosis in a Patient with Normal Renal Function. ( Ellen, R; Omar, A; Sorisky, A, 2016) |
| "The March 2012 regulatory action issued by the Japanese government signalled the rare but serious complication of lactic acidosis that can occur during metformin treatment, especially with the high dose formulation, h-metformin, and in those above 75 years old." | 7.81 | Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. ( Hanatani, T; Sai, K; Saito, Y; Segawa, K; Tohkin, M, 2015) |
| "Metformin-induced lactic acidosis is a rare but severe disease for the individual patients." | 7.81 | [Metformin-induced lactic acidosis : Severe symptoms with difficult diagnostics]. ( Brenner, T; Decker, SO; Hofer, S; Siegler, BH; Ulrich, A; Wortmann, M, 2015) |
| "The objective of this study was to determine whether treatment with metformin in patients with renal impairment is associated with a higher risk of lactic acidosis or elevated lactate concentrations compared with users of a noninsulin antidiabetic drug (NIAD) who had never used metformin." | 7.80 | Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. ( De Smet, PA; de Vries, F; Derijks, HJ; Egberts, A; Eppenga, WL; Geerts, AF; Lalmohamed, A; Wensing, M, 2014) |
| "There is controversy surrounding the risk of metformin and the development of lactic acidosis." | 7.80 | Pharmacist review prevents evolving metformin-associated lactic acidosis. ( Kyle, G; Naunton, M; Naunton-Boom, K; Owoka, F, 2014) |
| "The objective was to assess glucose, lactate, glycerol, and pyruvate concentrations in the interstitial fluid of the adipose tissue as well as the glucose relative recovery coefficient in reference to capillary blood (RC) during the first two days of the standard treatment of diabetic ketoacidosis (DKA) in patients with type 1 and type 2 diabetes." | 7.79 | Microdialysis monitoring of glucose, lactate, glycerol, and pyruvate in patients with diabetic ketoacidosis. ( Ciechanowska, A; Foltynski, P; Karnafel, W; Kawiak, J; Krzymien, J; Ladyzynski, P; Pulawska, E; Sabalinska, S; Wojcicki, JM, 2013) |
| " Two cases of lactic acidosis due to ingestion of high dose metformin for suicidal purposes have been presented here; in both cases, clinical improvement was seen with bicarbonate hemodialysis." | 7.77 | Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases. ( Aytemiz, E; Begenik, H; Emre, H; Erkoc, R; Ozturk, M; Soyoral, YU, 2011) |
| "The reported incidence of metformin associated lactic acidosis (MALA) in type 2 diabetes mellitus (DM) is 3-9 cases per 100,000 patient-years." | 7.77 | Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. ( Doorenbos, CJ; van Berlo-van de Laar, IR; Vermeij, CG, 2011) |
| "In type II diabetes treated with metformin, lactic acidosis is a rare but severe complication." | 7.72 | [Metformin-associated lactic acidosis precipitated by acute renal failure]. ( Azoulay, E; Galy-Floc'h, M; Mariot, J; Pertek, JP; Vidal, S, 2003) |
| "We report 4 cases of lactic acidosis in diabetic patients usually treated with metformin." | 7.72 | [Metformin-associated lactic acidosis remains a serious complication of metformin therapy]. ( Giunti, C; Grimaud, D; Ichai, C; Levraut, J; Orban, JC, 2003) |
| "Insulin, glucagon, glucose, nonesterified fatty acids (NEFA), and lactate response to oral glucose tolerance test (OGTT, 75 g glucose) and their correlation with mean blood pressure (BP), were studied in 10 normal subjects (N), 25 subjects with abdominal obesity (O), and 9 subjects with abdominal obesity and IGT or non-insulin-dependent diabetes (OD)." | 7.70 | Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension. ( Belfiore, F; Campione, R; Iannello, S, 1998) |
| "The biguanide drugs metformin and phenformin have been linked in the past to lactic acidosis, a metabolic condition associated with high rates of mortality." | 7.70 | Lactic acidosis in metformin therapy. ( Lalau, JD; Race, JM, 1999) |
| "The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years." | 7.69 | Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. ( Dailey, G; Gerich, JE; Nurjhan, N; Perriello, G; Stumvoll, M, 1995) |
| "A hemodialysed patient with abdominal pain, severe lactic acidosis and prolonged hypoglycemia is described." | 7.69 | Acute necrotizing pancreatitis, lactic acidosis and prolonged hypoglycemia in a hemodialysed patient--a logical but unfortunately fatal combination. ( Chagnac, A; Gafter, U; Halperin, M; Korzets, A; Ori, Y; Weinstein, T; Zevin, D, 1996) |
| "A 71 year old hypertensive, non insulin-dependent diabetic patient with moderate renal insufficiency taking 500 mg/d of metformin and 5 mg/d of enalapril, developed metabolic acidosis characterized by fairly elevated anion gap, hyperchloremia, severe hyperkaliemia, normal plasma level of 3-hydroxybutyric acid, absence of ketonuria and high plasma level of lactic acid." | 7.69 | Possible synergistic effect of metformin and enalapril on the development of hyperkaliemic lactic acidosis. ( Elisabetta, Z; Emanuela, M; Franzetti, I; Marco, G; Paolo, D; Renato, U, 1997) |
| "Phenformin-induced lactic acidosis has been thought to be rare in India due to a high carbohydrate intake, use of suboptimal doses of phenformin and a lesser prevalence of alcoholism, as compared to Western countries." | 7.68 | Biguanide-induced lactic acidosis. ( Chandalia, HB; Rangnath, M, 1990) |
| "Treatment with rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, in type 2 diabetic mellitus (T2DM) patients is under scrutiny because it affects adversely cardiovascular outcomes." | 6.79 | Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist. ( Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M, 2014) |
| "Metformin was prescribed to 99 patients (61%) ("M+"group) during the hospitalization, 62 patients were in "M-"group." | 5.91 | [Use of metformin in patients with type 2 diabetes and acute myocardial infarction: safety and impact on glycemic control]. ( Korotina, MA; Pochinka, IG; Strongin, LG, 2023) |
| " Metformin toxicity is a spectrum of conditions that may be differentiated into three subgroups: metformin-associated lactic acidosis (MALA), metformin-induced lactic acidosis (MILA), and metformin-unrelated lactic acidosis (MULA)." | 5.41 | High risk and low prevalence diseases: Metformin toxicities. ( Cao, JD; Koyfman, A; Long, B; Onisko, N; Rivera, D, 2023) |
| " Moreover, MET-associated lactic acidosis (MALA) needs to be considered and the incidence of MALA in patients with type 2 DM-TB coinfection remains unknown." | 5.27 | A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients. ( Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2018) |
| " However, if used in excessive doses for patients with kidney disease, it will be contraindicated with side effects such as lactic acidosis." | 5.22 | Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease. ( Rahman, F; Tuba, S, 2022) |
| "Twelve outpatients with type II diabetes mellitus and mild clinical signs and history of cardiac failure were studied to assess the effects of ibopamine on glucose and lipid metabolism." | 5.06 | Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study. ( Cicchetti, V; DiCarlo, A; Giannarelli, R; Marchetti, P; Navalesi, R; Sabino, F, 1990) |
| "Metformin-associated lactic acidosis (MALA) is a rare adverse effect that has significant morbidity and mortality." | 5.05 | Osmolar-gap in the setting of metformin-associated lactic acidosis: Case report and a literature review highlighting an apparently unusual association. ( Alamin, M; Elshafei, MN; Mohamed, MFH, 2020) |
| " The primary outcomes were mortality, occurrence of lactic acidosis and myocardial infarction (MI) in patients taking metformin during dialysis treatment for ≥12 months (long term)." | 5.01 | Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. ( Abdel Shaheed, C; Carland, JE; Chowdhury, G; Day, RO; Furlong, T; Graham, GG; Greenfield, JR; Hicks, M; Macdonald, P; Smith, FC; Smith, G; Stocker, SL; Williams, KM, 2019) |
| "Metformin-associated lactic acidosis (MALA) is a rare but potentially fatal condition that can easily be avoided." | 4.95 | [Metformin-associated lactic acidosis: an insufficiently recognised problem]. ( Bosch, FH; Kramers, C; Manders, M; van Luin, M, 2017) |
| " Metformin, however, is thought to increase the risk of lactic acidosis, and has been considered to be contraindicated in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age." | 4.86 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. ( Greyber, E; Pasternak, GA; Salpeter Posthumous, EE; Salpeter, SR, 2010) |
| " Metformin, however, is thought to increase the risk of lactic acidosis, and has been considered to be contraindicated in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age." | 4.86 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. ( Greyber, E; Pasternak, GA; Salpeter, EE; Salpeter, SR, 2010) |
| "Lactic acidosis is a disease in which lactic acid accumulates in the blood and causes acidosis in the patient." | 4.31 | Metformin-associated severe lactic acidosis combined with multi-organ insufficiency induced by infection with Aeromonas veronii: A case report. ( Wu, C; Xia, Y; Zhu, X, 2023) |
| "This study investigated the safe use of metformin in patients with (1) type 2 diabetes mellitus (T2DM) and heart failure on metformin, and (2) heart failure without T2DM and metformin naïve." | 4.31 | The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study. ( Carland, JE; Chowdhury, G; Day, RO; Graham, G; Greenfield, JR; Hayward, CS; Kumar, S; Kumarasinghe, G; Macdonald, P; Olsen, N; Stocker, SL, 2023) |
| "Metformin-associated lactic acidosis (MALA) is a widely documented adverse event of metformin." | 4.02 | The usefulness of measuring the anion gap in diagnosing metformin-associated lactic acidosis: a case series. ( Agra-Montava, I; Juanes-Borrego, A; Lozano-Polo, L; Mangues-Bafalluy, MA; Puig-Campmany, M; Ruiz-Ramos, J, 2021) |
| "The FDA approved 'label' for metformin lists hepatic insufficiency as a risk for lactic acidosis." | 3.96 | The safety and pharmacokinetics of metformin in patients with chronic liver disease. ( Braithwaite, HE; Carland, JE; Cheng, TS; Danta, M; Day, RO; Graham, GG; Greenfield, JR; Kumar, SS; Liu, Z; Smith, FC; Stocker, SL; Williams, KM, 2020) |
| "Metformin-associated lactic acidosis (MALA) carries a high mortality rate." | 3.96 | Metformin-associated lactic acidosis: reinforcing learning points. ( Creagh, F; Goonoo, MS; Morris, R; Raithatha, A, 2020) |
| " We report three cases of prospectively identified laboratory confirmed metformin-associated lactic acidosis admitted to our intensive care unit." | 3.91 | Laboratory-Confirmed Metformin-Associated Lactic Acidosis ( Canavan, C; Coyle, N; Nasim, S; Nestor, C, 2019) |
| "To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3-5." | 3.91 | Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: is it significant? ( Guddattu, V; Mareddy, AS; Nagaraju, SP; Prabhu, RA; Rangaswamy, D, 2019) |
| "Metformin-associated lactic acidosis is a rare but serious complication of taking metformin." | 3.91 | Metformin-Associated Lactic Acidosis Presenting Like Acute Mesenteric Ischemia. ( Hastings, C; Johnson, K; Slaven, E; Zhang, QC, 2019) |
| " We aimed to follow the variation of some biochemical and clinical parameters in T2D patients before and after Ramadan; and to determine the incidence of fasting on hypoglycaemia and lactic acidosis associated with antidiabetic agents such as metformin." | 3.91 | Follow-up of glycemic index before and after Ramadan fasting in type 2 diabetes patients under antidiabetic medications. ( Abdessadek, M; Ajdi, F; Khabbal, Y; Magoul, R; Marmouzi, I, 2019) |
| "Pharmacokinetic data suggest that the risk of metformin-associated lactic acidosis (MALA) may be increased after Roux-en-Y gastric bypass (RYGB) surgery." | 3.88 | Risk of Metformin-Associated Lactic Acidosis (MALA) in Patients After Gastric Bypass Surgery. ( Aarts, EO; Aelfers, SCW; Berends, FJ; de Boer, H; Deden, LN; Janssen, IMC; van Borren, MMGJ, 2018) |
| "In the general population, the absolute risk of lactic acidosis in patients treated with metformin appears to be low." | 3.88 | Safety of Metformin Therapy in Patients with Type 2 Diabetes Living on an Oxygen-Deficient Plateau, Tibet, China. ( Geng, Y; Lv, X; Meng, S; Mina, A; Puchi, B; Ren, Q; Song, J; Yang, L; Yang, S; Zhou, L, 2018) |
| "Metformin is renally excreted and has been associated with the development of lactic acidosis." | 3.85 | Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. ( Connelly, PJ; Donnelly, L; Lonergan, M; Pearson, ER; Soto-Pedre, E; Zhou, K, 2017) |
| " There was no difference in prevalence of hyperlactatemia and lactic acidosis between the patients with and without metformin use (18." | 3.85 | Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. ( Cha, BS; Han, E; Hwang, S; Kang, ES; Kang, HP; Lee, BW; Lee, EY; Lee, HC; Lee, SH; Lee, W; Lee, YH; Lee, YM, 2017) |
| "The role of metformin in lactic acidosis is regularly questioned." | 3.83 | Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. ( Altman, JJ; Boucaud-Maitre, D; Bouhanick, B; Doucet, J; Emmerich, J; Girardin, E; Kaloustian, E; Lassmann Vague, V; Porokhov, B; Ropers, J, 2016) |
| "To evaluate the strength of association between lactic acidosis (LA) and well-recognized risk factors for LA, particularly the weight of metformin." | 3.83 | Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University. ( Chanoine, S; Giai, J; Lepelley, M; Villier, C; Yahiaoui, N, 2016) |
| "We report a case of metformin-associated lactic acidosis (MALA) in the setting of normal renal function and review the relevant medical literature." | 3.83 | Metformin-Associated Lactic Acidosis in a Patient with Normal Renal Function. ( Ellen, R; Omar, A; Sorisky, A, 2016) |
| "The March 2012 regulatory action issued by the Japanese government signalled the rare but serious complication of lactic acidosis that can occur during metformin treatment, especially with the high dose formulation, h-metformin, and in those above 75 years old." | 3.81 | Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. ( Hanatani, T; Sai, K; Saito, Y; Segawa, K; Tohkin, M, 2015) |
| "Metformin-induced lactic acidosis is a rare but severe disease for the individual patients." | 3.81 | [Metformin-induced lactic acidosis : Severe symptoms with difficult diagnostics]. ( Brenner, T; Decker, SO; Hofer, S; Siegler, BH; Ulrich, A; Wortmann, M, 2015) |
| " However, due to its rare association with lactic acidosis, its safety in COPD is uncertain." | 3.81 | Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. ( Archer, JR; Baker, EH; Hitchings, AW; Srivastava, SA, 2015) |
| "In a number of patients, the antidiabetic drug metformin has been associated with lactic acidosis." | 3.80 | Metformin in peritoneal dialysis: a pilot experience. ( Abdul-Rahman, IS; Al-Hwiesh, AK; Al-Mohanna, FA; Divino-Filho, JC; El-Deen, MA; Gupta, KL; Larbi, E, 2014) |
| "The objective of this study was to determine whether treatment with metformin in patients with renal impairment is associated with a higher risk of lactic acidosis or elevated lactate concentrations compared with users of a noninsulin antidiabetic drug (NIAD) who had never used metformin." | 3.80 | Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. ( De Smet, PA; de Vries, F; Derijks, HJ; Egberts, A; Eppenga, WL; Geerts, AF; Lalmohamed, A; Wensing, M, 2014) |
| "There is controversy surrounding the risk of metformin and the development of lactic acidosis." | 3.80 | Pharmacist review prevents evolving metformin-associated lactic acidosis. ( Kyle, G; Naunton, M; Naunton-Boom, K; Owoka, F, 2014) |
| "The objective was to assess glucose, lactate, glycerol, and pyruvate concentrations in the interstitial fluid of the adipose tissue as well as the glucose relative recovery coefficient in reference to capillary blood (RC) during the first two days of the standard treatment of diabetic ketoacidosis (DKA) in patients with type 1 and type 2 diabetes." | 3.79 | Microdialysis monitoring of glucose, lactate, glycerol, and pyruvate in patients with diabetic ketoacidosis. ( Ciechanowska, A; Foltynski, P; Karnafel, W; Kawiak, J; Krzymien, J; Ladyzynski, P; Pulawska, E; Sabalinska, S; Wojcicki, JM, 2013) |
| "Metformin therapy is limited in patients with chronic kidney disease (CKD) due to the potential risk of lactic acidosis." | 3.78 | Metformin therapy in patients with chronic kidney disease. ( Day, RO; Duong, JK; Furlong, TJ; Graham, GG; Greenfield, JR; Kirkpatrick, CM; Kumar, SS; Roberts, DM; Williams, KM, 2012) |
| " Two cases of lactic acidosis due to ingestion of high dose metformin for suicidal purposes have been presented here; in both cases, clinical improvement was seen with bicarbonate hemodialysis." | 3.77 | Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases. ( Aytemiz, E; Begenik, H; Emre, H; Erkoc, R; Ozturk, M; Soyoral, YU, 2011) |
| "The reported incidence of metformin associated lactic acidosis (MALA) in type 2 diabetes mellitus (DM) is 3-9 cases per 100,000 patient-years." | 3.77 | Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. ( Doorenbos, CJ; van Berlo-van de Laar, IR; Vermeij, CG, 2011) |
| "The relationship among metformin use, plasma lactate levels, and lactic acidosis in patients with type 2 diabetes mellitus and the appropriateness of metformin use in patients with renal dysfunction are discussed." | 3.75 | Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? ( Ernst, ME; McDanel, DL; Moores, KG; Philbrick, AM; Ross, MB, 2009) |
| "In order to better understand the impact of reduced mitochondrial function for the development of insulin resistance and cellular metabolism, human myotubes were established from lean, obese, and T2D subjects and exposed to mitochondrial inhibitors, either affecting the electron transport chain (Antimycin A), the ATP synthase (oligomycin) or respiratory uncoupling (2,4-dinitrophenol)." | 3.74 | Insulin resistance and the mitochondrial link. Lessons from cultured human myotubes. ( Gaster, M, 2007) |
| " This is largely due to the historical experience of lactic acidosis with phenformin, despite the fact that metformin does not predispose to this when compared with other therapies." | 3.73 | Contraindications can damage your health--is metformin a case in point? ( Holstein, A; Stumvoll, M, 2005) |
| " Myocardial ischemia after coronary angioplasty was evaluated in 20 nondiabetic and 23 diabetic patients chronically taking either glibenclamide or glimepiride." | 3.72 | Impairment of myocardial protection in type 2 diabetic patients. ( Chou, TF; Lee, TM, 2003) |
| "In type II diabetes treated with metformin, lactic acidosis is a rare but severe complication." | 3.72 | [Metformin-associated lactic acidosis precipitated by acute renal failure]. ( Azoulay, E; Galy-Floc'h, M; Mariot, J; Pertek, JP; Vidal, S, 2003) |
| "We report 4 cases of lactic acidosis in diabetic patients usually treated with metformin." | 3.72 | [Metformin-associated lactic acidosis remains a serious complication of metformin therapy]. ( Giunti, C; Grimaud, D; Ichai, C; Levraut, J; Orban, JC, 2003) |
| "Insulin, glucagon, glucose, nonesterified fatty acids (NEFA), and lactate response to oral glucose tolerance test (OGTT, 75 g glucose) and their correlation with mean blood pressure (BP), were studied in 10 normal subjects (N), 25 subjects with abdominal obesity (O), and 9 subjects with abdominal obesity and IGT or non-insulin-dependent diabetes (OD)." | 3.70 | Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension. ( Belfiore, F; Campione, R; Iannello, S, 1998) |
| "Young first-degree relatives of type 2 diabetic patients are insulin-resistant, with the insulin resistance mainly located in skeletal muscle due to decreased insulin-induced nonoxidative glucose metabolism and muscle glycogen synthase activation." | 3.70 | Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. ( Alford, F; Beck-Nielsen, H; Handberg, A; Henriksen, JE; Vaag, A, 1999) |
| "The biguanide drugs metformin and phenformin have been linked in the past to lactic acidosis, a metabolic condition associated with high rates of mortality." | 3.70 | Lactic acidosis in metformin therapy. ( Lalau, JD; Race, JM, 1999) |
| "The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years." | 3.69 | Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. ( Dailey, G; Gerich, JE; Nurjhan, N; Perriello, G; Stumvoll, M, 1995) |
| "A hemodialysed patient with abdominal pain, severe lactic acidosis and prolonged hypoglycemia is described." | 3.69 | Acute necrotizing pancreatitis, lactic acidosis and prolonged hypoglycemia in a hemodialysed patient--a logical but unfortunately fatal combination. ( Chagnac, A; Gafter, U; Halperin, M; Korzets, A; Ori, Y; Weinstein, T; Zevin, D, 1996) |
| "A 71 year old hypertensive, non insulin-dependent diabetic patient with moderate renal insufficiency taking 500 mg/d of metformin and 5 mg/d of enalapril, developed metabolic acidosis characterized by fairly elevated anion gap, hyperchloremia, severe hyperkaliemia, normal plasma level of 3-hydroxybutyric acid, absence of ketonuria and high plasma level of lactic acid." | 3.69 | Possible synergistic effect of metformin and enalapril on the development of hyperkaliemic lactic acidosis. ( Elisabetta, Z; Emanuela, M; Franzetti, I; Marco, G; Paolo, D; Renato, U, 1997) |
| "The effect of metformin on glucose metabolism was examined in eight obese (percent ideal body weight, 151 +/- 9%) and six lean (percent ideal body weight, 104 +/- 4%) noninsulin-dependent diabetic (NIDD) subjects before and after 3 months of metformin treatment (2." | 3.68 | Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. ( Barzilai, N; DeFronzo, RA; Simonson, DC, 1991) |
| "Phenformin-induced lactic acidosis has been thought to be rare in India due to a high carbohydrate intake, use of suboptimal doses of phenformin and a lesser prevalence of alcoholism, as compared to Western countries." | 3.68 | Biguanide-induced lactic acidosis. ( Chandalia, HB; Rangnath, M, 1990) |
| " There were no severe or serious adverse events (SAEs) and no increase in lactic acid concentration was reported during the study." | 3.01 | Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. ( Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021) |
| "Patients with type 2 diabetes mellitus (T2DM) are at increased risk of developing neurodegenerative diseases." | 2.84 | Effects of Cycling and Exergaming on Neurotrophic Factors in Elderly Type 2 Diabetic Men - A Preliminary Investigation. ( Bloch, W; Brinkmann, C; Brixius, K; Latsch, J; Lay, D; Masoud, M; Schäfer, L, 2017) |
| " Pharmacokinetic curves were recorded at steady-state." | 2.84 | Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. ( Aarnoutse, RE; Burger, DM; Colbers, A; de Kanter, CTMM; Drenth, JPH; Smolders, EJ; Tack, CJ; van Ewijk-Beneken Kolmer, N; Velthoven-Graafland, K; Wolberink, LT, 2017) |
| "Bradykinin and insulin were analyzed before and at 45 min post-exercise." | 2.84 | Bradykinin, insulin, and glycemia responses to exercise performed above and below lactate threshold in individuals with type 2 diabetes. ( Arsa, G; Asano, RY; Atlas, SE; Browne, RAV; Coelho-Júnior, HJ; Lewis, JE; Moraes, JFVN; Moraes, MR; Oliveira-Silva, I; Sales, MM; Simões, HG, 2017) |
| "Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are associated with macro- and microcirculatory complications that reduce physical performance." | 2.82 | Effects of Wearing Compression Stockings on the Physical Performance of T2DM Men with MetS. ( Bloch, W; Brinkmann, C; Brixius, K; Grau, M; Hermann, R; Kerzel, H; Kohl-Bareis, M; Latsch, J; Reinhardt, L; Rühl, E, 2016) |
| "Treatment with rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, in type 2 diabetic mellitus (T2DM) patients is under scrutiny because it affects adversely cardiovascular outcomes." | 2.79 | Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist. ( Ala-Korpela, M; Badeau, RM; Honka, MJ; Kangas, AJ; Lautamäki, R; Nuutila, P; Soininen, P; Stewart, M, 2014) |
| "In a population based cohort study 134 type 2 diabetes patients were examined at baseline and 3-year follow-up." | 2.75 | Low plasma lactate concentration as a biomarker of an incompetent brain-pull: a risk factor for weight gain in type 2 diabetes patients. ( Hitze, B; Hubold, C; Lehnert, H; Marxsen, A; Meier, S; Oltmanns, KM; Pellerin, L; Peters, A; Schweiger, U; van Dyken, R, 2010) |
| "Glycerol concentration was 267 +/- 41 micromol/L and 133 +/- 40 micromol/L in PF and venous blood, respectively (P = 0." | 2.73 | Microdialysis technique as a monitoring system for acute complications of diabetes. ( Ciechanowska, A; Foltynski, P; Karnafel, W; Kawiak, J; Krzymien, J; Ladyzynski, P; Pulawska, E; Sabalinska, S; Wojcicki, JM, 2008) |
| "0 mg/metformin (M) 400 mg combination with a G 2." | 2.71 | Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial. ( Brunetti, P; Gori, M; Pagano, G; Perriello, G; Turco, C, 2004) |
| "This study aimed to evaluate hemodynamic changes associated with propionyl-L-carnitine and L-carnitine administration and its correlation with biochemical markers of cardiac vascular function." | 2.71 | Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. ( Lango, R; Lysiak-Szydłowska, W; Rogowski, J; Siebert, J; Smoleński, RT; Słomińska, EM; Wujtewicz, M; Yacoub, MH, 2005) |
| "During fasting, NIDDM hearts demonstrated lower fractional extraction of glucose from arterial plasma than controls (1." | 2.70 | Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. ( Concato, J; Jagasia, D; McNulty, PH; Pfau, S; Whiting, JM, 2001) |
| "Metformin-treated patients had higher plasma lactate concentrations than nonmetformin-treated subjects (geometric mean [s." | 2.70 | The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. ( Bruce, DG; Chubb, P; Davis, TM; Davis, WA; Jackson, D, 2001) |
| "In this study nine patients with Type 2 diabetes mellitus were subjected to four treatments in random order on separate days: (A) endurance exercise after the administration of 3." | 2.69 | The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus. ( Bungert, S; Gudat, U; Heinemann, L; Kemmer, F, 1998) |
| "Persons with type II diabetes mellitus (DM), even without cardiovascular complications have a decreased maximal oxygen consumption (VO2 max) and submaximal oxygen consumption (VO2) during graded exercise compared with healthy controls." | 2.69 | Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. ( Bauer, TA; Brandenburg, SL; Eckel, RH; Hiatt, WR; Regensteiner, JG; Reusch, JE; Sippel, JM; Smith, S; Vogelsong, AM; Wolfel, EE, 1998) |
| "Defective GS activity in obese NIDDM patients is not secondary to hyperglycemia." | 2.69 | Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. ( Beck-Nielsen, H; Damsbo, P; Hermann, LS; Hother-Nielsen, O; Vaag, A, 1998) |
| "4." | 2.69 | Levels of lactic acid, normal level & its relation to food, glucose, cholesterol, raised blood urea and phenformin therapy. ( Amin, BM; Patel, JC; Sawant, MS, 2000) |
| "Metformin was clinically well-tolerated." | 2.68 | Is metformin safe enough for ageing type 2 diabetic patients? ( Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Testa, I, 1996) |
| "Metformin treatment significantly reduced fasting plasma glucose (196 +/- 18 vs." | 2.68 | Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. ( Consoli, A; Cusi, K; DeFronzo, RA, 1996) |
| "The acipimox and placebo treatments were separated by a 2-week washout period." | 2.67 | Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. ( Beck-Nielsen, H; Henriksen, JE; Melander, A; Thye-Rønn, P; Vaag, A; Worm, D, 1994) |
| "Metformin treatment significantly reduced mean day-time plasma glucose levels (10." | 2.66 | Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. ( Andersen, PH; Beck-Nielsen, H; Hother-Nielsen, O; Pedersen, O; Schmitz, O, 1989) |
| "Metformin was prescribed to 99 patients (61%) ("M+"group) during the hospitalization, 62 patients were in "M-"group." | 1.91 | [Use of metformin in patients with type 2 diabetes and acute myocardial infarction: safety and impact on glycemic control]. ( Korotina, MA; Pochinka, IG; Strongin, LG, 2023) |
| "Metformin is a biguanide compound commonly applied in humans with type 2 diabetes." | 1.72 | Regulatory Effects of Metformin, an Antidiabetic Biguanide Drug, on the Metabolism of Primary Rat Adipocytes. ( Konieczna, K; Szkudelska, K; Szkudelski, T, 2022) |
| "Sixty-three Lebanese patients with type 2 diabetes who administered metformin, were followed up for six months and genotyped for rs622342A>C." | 1.56 | rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response. ( El Shamieh, S; Fakhoury, R; Naja, K, 2020) |
| "First, in the dose-finding study, the appropriate daily dosing schedules were 1,500 mg (0." | 1.48 | Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. ( Belpaire, F; Bennis, Y; De Broe, ME; Hurtel-Lemaire, AS; Kajbaf, F; Lalau, JD, 2018) |
| " Herein, we describe a method for the separation and determination of lactic acid and 2-hydroxyglutaric acid enantiomers by chiral derivatization (with l-menthol and acetyl chloride) combined with gas chromatography and mass spectrometry." | 1.48 | Separation and determination of the enantiomers of lactic acid and 2-hydroxyglutaric acid by chiral derivatization combined with gas chromatography and mass spectrometry. ( Ding, X; Liang, J; Lin, S; Weng, H, 2018) |
| "Glycogen storage disease type Ia is a genetic disorder that is associated with persistent fasting hypoglycemia and the inability to produce endogenous glucose." | 1.46 | Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report. ( Cohn, A; Ohri, A, 2017) |
| "In contrast, type 2 diabetes makes the heart metabolise more fatty acids." | 1.43 | Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation. ( Aasum, E; Aksentijevic, D; Carr, CA; Clarke, K; Cole, MA; Heather, LC; Le Page, L; Lund, T; Mansor, LS; Mehta, K; Shattock, MJ; Sousa Fialho, Mda L; Tyler, DJ, 2016) |
| "Metformin is a biguanaide antidiabetic drug used worldwide, and its effectiveness and benefits have already been established." | 1.43 | Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin. ( Hiraoka, S; Nishihara, M; Tsuji, H; Yokoyama, S, 2016) |
| " A population model was used to determine the pharmacokinetic parameters." | 1.42 | The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. ( Day, RO; Duong, JK; Furlong, TJ; Graham, GG; Greenfield, JR; Kirkpatrick, CM; Kumar, SS; Williams, KM, 2015) |
| "Patients suffering from type 2 diabetes mellitus (T2DM) often exhibit chronic elevated lactate levels which can promote peripheral insulin resistance by disturbing skeletal muscle insulin-signaling." | 1.40 | Endurance training alters skeletal muscle MCT contents in T2DM men. ( Bloch, W; Brinkmann, C; Brixius, K; Hellmich, M; Hermann, R; Lenzen, E; Opitz, D; Schiffer, T, 2014) |
| "Oxidative capacity is decreased in type 2 diabetes." | 1.39 | Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study. ( Ballantyne, CM; Brancati, FL; Chu, AY; Guallar, E; Hoogeveen, RC; Juraschek, SP; Miller, ER; Pankow, JS; Schmidt, MI; Shantha, GP; Young, JH, 2013) |
| "In the type 2 diabetes model GABA levels were increased suggesting that brain glycogen serves a role in maintaining a proper ratio between excitatory and inhibitory neurotransmitters in type 2 diabetes." | 1.38 | Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model. ( Benie, AJ; Bouman, SD; Schousboe, A; Sickmann, HM; Waagepetersen, HS, 2012) |
| "Eleven patients with type 2 diabetes participated in two experimental sessions; one was a 30-min EMS 30 min after a breakfast (EMS trial) and the other was a complete rest after a breakfast (Control trial)." | 1.38 | Effect of percutaneous electrical muscle stimulation on postprandial hyperglycemia in type 2 diabetes. ( Fukuda, K; Kimura, T; Matsubara, Y; Miyamoto, T; Moritani, T; Tsuda, K, 2012) |
| "Fasting whole blood specimens of 392 type 2 diabetes patients treated with metformin (n=199) or not (n=193) were collected." | 1.38 | The gonadal hormone regulates the plasma lactate levels in type 2 diabetes treated with and without metformin. ( Jia, W; Li, Q; Liu, F; Lu, F; Lu, H; Shen, Y; Tang, J; Zheng, T, 2012) |
| "Non-healing diabetic foot ulcers are characterized by high wound fluid lactate levels." | 1.37 | Wound fluid lactate concentration: a helpful marker for diagnosing soft-tissue infection in diabetic foot ulcers? Preliminary findings. ( Beckert, S; Bühler, S; Königsrainer, A; Königsrainer, I; Löb, S; Löffler, M; Northoff, H; Symons, S; Weinreich, J; Zieker, D, 2011) |
| "The prevalence of type 2 diabetes rose across lactate quartiles (11, 14, 20 and 30%; P for trend <0." | 1.36 | Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. ( Astor, BC; Ballantyne, CM; Brancati, FL; Crawford, SO; Hoogeveen, RC; Schmidt, MI; Young, JH, 2010) |
| "Metformin is a worldwide accepted biguanide antidiabetic agent, and its effectiveness and benefit have already been well established." | 1.36 | Fasting plasma lactate concentrations in ambulatory elderly patients with type 2 diabetes receiving metformin therapy: a retrospective cross-sectional study. ( Lin, HD; Lin, LY; Lin, YC; Wang, HF, 2010) |
| "Nine men with type 2 diabetes (47." | 1.35 | Methods to identify the lactate and glucose thresholds during resistance exercise for individuals with type 2 diabetes. ( Arsa, G; Campbell, CS; Lima, LC; Moreira, SR; Oliveira, HB; Simões, HG, 2008) |
| "Diabetic retinopathy is one of the most common complications in diabetes mellitus due to persistent hyperglycaemia." | 1.35 | Alteration of timing of secretion of vascular endothelial growth factors is responsible for progression of diabetic retinopathy. ( Baidya, KP; Bandyopadhyay, R; Bhaduri, G; Bhattacharya, B; Mondal, LK, 2008) |
| "and results Left ventricular hypertrophy was induced surgically in Sprague-Dawley rats by inter-renal aortic constriction." | 1.35 | Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy. ( Akki, A; Seymour, AM, 2009) |
| "Insulin resistance in subjects with type 2 diabetes (T2D) and obesity is associated with an imbalance between the availability and the oxidation of lipids." | 1.35 | Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training. ( Beck-Nielsen, H; Højlund, K; Mogensen, M; Sahlin, K; Vind, BF, 2009) |
| "Metformin is an anti-diabetic agent that has been reported to decrease plasma glucose by multiple mechanisms, such as decreasing hepatic glucose production and activating peripheral glucose utilization." | 1.35 | Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. ( Fujiwara, T; Hagisawa, Y; Kanda, S; Nakashima, R; Ogawa, J; Okuno, A; Takahashi, K; Tanaka, J; Yoshida, T, 2009) |
| "The lactic acid was assayed by enzyme-electrode method." | 1.35 | Relationship of plasma creatinine and lactic acid in type 2 diabetic patients without renal dysfunction. ( Hou, XH; Jia, WP; Li, L; Liu, F; Lu, HJ; Lu, JX; Tang, JL; Xiang, KS, 2009) |
| "Repaglinide (RPG) is an oral hypoglycemic agent with excellent bioavailability (90-98%) and a short plasma half-life (2-6 h)." | 1.35 | Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. ( Jain, S; Saraf, S, 2009) |
| "D-mannose is an essential monosaccharide constituent of glycoproteins and glycolipids." | 1.33 | Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration. ( Asano, N; Miwa, I; Mizutani, T; Nakajima, H; Taguchi, T; Yabuuchi, M; Yamashita, E, 2005) |
| "Thus in type 2 diabetes, postprandial hyperglycemia is primarily due to increased glucose release; hyperglycemia overcomes the effects of impaired insulin secretion and sensitivity on glucose transport, but intracellular defects persist so that pathways of glucose metabolism are abnormal and glucose is shunted away from normal sites of storage (e." | 1.33 | Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. ( Dostou, JM; Gerich, JE; Gosmanov, NR; Meyer, C; Szoke, E; Welle, SL; Wittlin, SD; Woerle, HJ, 2006) |
| "Fifty patients of type 2 diabetes mellitus of 10-12 years duration, without retinopathy, constituted the study group." | 1.33 | Relation between increased anaerobic glycolysis and visual acuity in long-standing type 2 diabetes mellitus without retinopathy. ( Baidya, KP; Bhaduri, G; Bhattacharya, B; Giri, A; Mondal, LK, 2006) |
| "Gluconeogenesis is increased in type 2 diabetes and contributes significantly to fasting and postprandial hyperglycemia." | 1.33 | Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. ( Chandramouli, VC; Dang, Q; Erion, MD; Landau, BR; Potter, SC; van Poelje, PD, 2006) |
| "Subjects with diet-controlled type 2 diabetes (n = 9) and age- and body mass index-matched nondiabetic controls (n = 9) were studied." | 1.32 | Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects. ( Carey, PE; Halliday, J; Morris, PG; Snaar, JE; Taylor, R, 2003) |
| "Ten patients with type 2 diabetes and ten healthy controls matched for sex, age, and body mass index were investigated." | 1.31 | Estimations of muscle interstitial insulin, glucose, and lactate in type 2 diabetic subjects. ( Holmäng, A; Lönnroth, P; Sjöstrand, M; Strindberg, L, 2000) |
| "Glycerol release (GR) was used to assess the lipolytic rate and was highest in LW in the abdominal area [0 h: LW, 1." | 1.31 | Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa. ( Boyd, IH; Crowther, NJ; Gray, IP; Joffe, BI; Lönnroth, PN; Schlaphoff, GP; van der Merwe, MT, 2001) |
| "We concluded that although NIDDM is not associated with an intrinsic alteration in hepatic sensitivity to glucagon, it does alter the relative contributions of the direct and indirect pathways to nocturnal glycogen synthesis." | 1.30 | Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis. ( Basu, A; Dinneen, SF; Nielsen, MF; Rizza, RA; Schwenk, WF; Wise, S, 1997) |
| "Dodecanedioic acid (C12) is an even-numbered dicarboxylic acid (DA)." | 1.30 | The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. ( Benedetti, G; Capristo, E; De Gaetano, A; Gasbarrini, G; Greco, AV; Mingrone, G, 1998) |
| "We conclude that in type 2 diabetes, both liver and kidney contribute to glucose overproduction and that renal glucose uptake is markedly increased." | 1.30 | Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. ( Dostou, J; Gerich, J; Meyer, C; Mitrakou, A; Nadkarni, V; Stumvoll, M, 1998) |
| "We studied seven obese subjects with type 2 diabetes and seven lean and seven obese control subjects (fasting plasma glucose levels, 7." | 1.30 | Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia. ( Giacca, A; Groenewoud, Y; McClean, P; Tsui, E; Zinman, B, 1998) |
| "Zucker diabetic fatty rats develop type 2 diabetes concomitantly with peripheral insulin resistance." | 1.30 | Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats. ( Barberà, A; Guinovart, JJ; Newgard, CB; Seoane, J; Télémaque-Potts, S, 1999) |
| "To evaluate the influence of NIDDM on subcutaneous adipose tissue metabolism microdialysis combined with 133Xe clearance and measurements in arterialized plasma were carried out using samples of subcutaneous abdominal fat from nine obese NIDDM subjects (glucose, 7." | 1.29 | Microdialysis assessment of adipose tissue metabolism in post-absorptive obese NIDDM subjects. ( Jansson, PA; Lönnroth, P; Smith, U, 1995) |
| "Thus, in NIDDM patients, fasting corrects the defect in glycogen storage without modifying the action of insulin on glucose uptake and improves beta-cell responsiveness, the latter two effects being opposite to those observed in nondiabetic subjects." | 1.29 | Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM. ( Balasse, EO; Féry, F, 1994) |
| "4." | 1.29 | Levels of lactic acid in normal Indians & its relation to food, glucose, cholesterol, raised blood urea. ( Patel, JC; Sawant, MS, 1993) |
| "Metformin treatment almost normalized glycogen levels, whereas lactate declined concomitantly in the pellet." | 1.29 | Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin. ( Belleville, I; Martinand, A; Rapin, JR; Wiernsperger, NF; Yoa, RG, 1993) |
| "In conclusion, in NIDDM: (a) insulin resistance involves glycolysis, glycogen synthesis, and glucose oxidation; (b) hyperglycemia and hyperinsulinemia can normalize total body glucose uptake; (c) marked hyperinsulinemia normalizes glycogen synthesis and total flux through glycolysis, but does not restore a normal distribution between oxidation and nonoxidative glycolysis; (d) hyperglycemia cannot overcome the defects in glucose oxidation and nonoxidative glycolysis; (e) lipid oxidation is elevated and is suppressed only with hyperinsulinemia." | 1.29 | Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. ( Bonadonna, RC; Bonora, E; DeFronzo, RA; Del Prato, S; Gulli, G; Shank, M; Solini, A, 1993) |
| "A 64-year-old female with McArdle's disease and non-insulin-dependent diabetes mellitus (NIDDM) is reported." | 1.29 | McArdle's disease with non-insulin-dependent diabetes mellitus: the beneficial effects of hyperglycemia and hyperinsulinemia for exercise intolerance. ( Amano, K; Ichikawa, Y; Kono, N; Maruyama, H; Nakamoto, S; Saruta, T; Takei, I; Yamauchi, A, 1996) |
| "Metformin treatment did not lead to an increase of the patients body weight." | 1.29 | [The effect of metformin on lactate levels in type II diabetes]. ( Cacáková, V; Perusicová, J; Richtrová, A, 1996) |
| "Fourteen patients with NIDDM (mean +/- SE age 61 +/- 2 yr, fasting plasma glucose 11." | 1.28 | No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients. ( Koivisto, VA; Puhakainen, I; Yki-Järvinen, H, 1991) |
| "Biguanides were found to be conducive to normalization of thrombelastogram values, not elevating the blood serum content of lactic acid even after exercise test." | 1.28 | [Effect of biguanides on the indicators of thrombelastography and the level of lactic acid in diabetes mellitus]. ( Babenko, AIu; Blagosklonnaia, IaV; Krasil'nikova, EI; Zaĭed, N, 1990) |
| "Nox was greater in NIDDM (P less than 0." | 1.28 | Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. ( Bulacan, F; Gumbiner, B; Henry, RR; Thorburn, AW; Wallace, P, 1990) |
| " Insulin dose-response curves revealed similar sensitivities and responsiveness." | 1.28 | Effect of insulin on glucose utilization in epitrochlearis muscle of rats with streptozocin-induced NIDDM. ( Gavin, JR; Karl, IE; Levy, J, 1990) |
| "The metformin dosage was 1 g twice daily in 9 of the patients and 850 mg thrice daily in the 10th subject." | 1.27 | Mechanism of metformin action in non-insulin-dependent diabetes. ( Disilvio, L; Featherbe, D; Hawa, MI; Jackson, RA; Jaspan, JB; Kurtz, AB; Sim, BM, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (4.58) | 18.7374 |
| 1990's | 67 (23.59) | 18.2507 |
| 2000's | 62 (21.83) | 29.6817 |
| 2010's | 110 (38.73) | 24.3611 |
| 2020's | 32 (11.27) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 1 |
| Wang, S | 1 |
| Liu, X | 3 |
| Sheng, Z | 1 |
| Li, B | 1 |
| Li, J | 1 |
| Zhang, J | 2 |
| Zhang, Z | 3 |
| Cai, H | 1 |
| Wang, X | 2 |
| Chen, J | 2 |
| Wang, F | 2 |
| Wang, L | 1 |
| Liu, J | 2 |
| Zhao, Y | 1 |
| Zhang, Y | 1 |
| Qi, M | 1 |
| Ping, F | 1 |
| Zhang, H | 2 |
| Xu, L | 1 |
| Li, W | 1 |
| Li, Y | 2 |
| Theurey, P | 1 |
| Vial, G | 1 |
| Fontaine, E | 1 |
| Monternier, PA | 1 |
| Fouqueray, P | 1 |
| Bolze, S | 1 |
| Moller, DE | 1 |
| Hallakou-Bozec, S | 1 |
| Johanns, M | 1 |
| Corbet, C | 1 |
| Jacobs, R | 1 |
| Drappier, M | 1 |
| Bommer, GT | 1 |
| Herinckx, G | 1 |
| Vertommen, D | 1 |
| Tajeddine, N | 1 |
| Young, D | 1 |
| Messens, J | 1 |
| Feron, O | 1 |
| Steinberg, GR | 1 |
| Hue, L | 1 |
| Rider, MH | 1 |
| Li, VL | 1 |
| He, Y | 1 |
| Contrepois, K | 1 |
| Liu, H | 1 |
| Kim, JT | 1 |
| Wiggenhorn, AL | 1 |
| Tanzo, JT | 1 |
| Tung, AS | 1 |
| Lyu, X | 1 |
| Zushin, PH | 1 |
| Jansen, RS | 1 |
| Michael, B | 1 |
| Loh, KY | 1 |
| Yang, AC | 1 |
| Carl, CS | 1 |
| Voldstedlund, CT | 1 |
| Wei, W | 1 |
| Terrell, SM | 1 |
| Moeller, BC | 1 |
| Arthur, RM | 1 |
| Wallis, GA | 1 |
| van de Wetering, K | 1 |
| Stahl, A | 1 |
| Kiens, B | 1 |
| Richter, EA | 2 |
| Banik, SM | 1 |
| Snyder, MP | 1 |
| Xu, Y | 2 |
| Long, JZ | 1 |
| Szkudelski, T | 1 |
| Konieczna, K | 1 |
| Szkudelska, K | 1 |
| Yong, Z | 1 |
| Ruiqi, W | 1 |
| Yanan, Y | 1 |
| Ning, M | 1 |
| Zhi, Z | 1 |
| Yinfeng, T | 1 |
| Lin, D | 1 |
| Yiying, L | 1 |
| Weiying, L | 1 |
| Chongming, W | 1 |
| Xiaopo, Z | 1 |
| Pang, H | 1 |
| Huang, X | 2 |
| Xu, ZP | 1 |
| Chen, C | 2 |
| Han, FY | 1 |
| Rahman, F | 1 |
| Tuba, S | 1 |
| Xia, Y | 1 |
| Zhu, X | 2 |
| Wu, C | 1 |
| Korotina, MA | 1 |
| Pochinka, IG | 1 |
| Strongin, LG | 1 |
| Chowdhury, G | 2 |
| Carland, JE | 3 |
| Kumar, S | 1 |
| Olsen, N | 1 |
| Graham, G | 1 |
| Kumarasinghe, G | 1 |
| Hayward, CS | 1 |
| Greenfield, JR | 6 |
| Macdonald, P | 2 |
| Day, RO | 5 |
| Stocker, SL | 3 |
| Ma, YL | 1 |
| Ke, JF | 1 |
| Wang, JW | 1 |
| Wang, YJ | 1 |
| Xu, MR | 1 |
| Li, LX | 1 |
| Rivera, D | 1 |
| Onisko, N | 1 |
| Cao, JD | 1 |
| Koyfman, A | 1 |
| Long, B | 1 |
| Choi, YS | 1 |
| Song, JE | 1 |
| Kim, E | 1 |
| Kim, CH | 1 |
| Lee, JE | 1 |
| Song, HT | 1 |
| Azushima, K | 1 |
| Kovalik, JP | 1 |
| Yamaji, T | 1 |
| Ching, J | 1 |
| Chng, TW | 1 |
| Guo, J | 1 |
| Liu, JJ | 1 |
| Nguyen, M | 1 |
| Sakban, RB | 1 |
| George, SE | 1 |
| Tan, PH | 1 |
| Lim, SC | 2 |
| Gurley, SB | 1 |
| Coffman, TM | 1 |
| Abdel Shaheed, C | 1 |
| Graham, GG | 4 |
| Smith, G | 1 |
| Hicks, M | 1 |
| Williams, KM | 4 |
| Furlong, T | 1 |
| Smith, FC | 2 |
| Mieno, H | 1 |
| Marunaka, Y | 1 |
| Inaba, T | 1 |
| Kojima, K | 1 |
| Yoneda, K | 1 |
| Nagata, K | 1 |
| Sotozono, C | 1 |
| Nestor, C | 1 |
| Nasim, S | 1 |
| Coyle, N | 1 |
| Canavan, C | 1 |
| Soya, M | 1 |
| Jesmin, S | 1 |
| Shima, T | 1 |
| Matsui, T | 1 |
| Soya, H | 1 |
| Gosmanova, EO | 1 |
| Shahzad, SR | 1 |
| Sumida, K | 1 |
| Kovesdy, CP | 1 |
| Gosmanov, AR | 1 |
| Morrow, B | 1 |
| Malkoc, A | 1 |
| Gong, T | 1 |
| Probst, D | 1 |
| Lin, C | 1 |
| Sen, A | 2 |
| La Belle, JT | 1 |
| Higuchi, I | 1 |
| Kimura, Y | 1 |
| Kobayashi, M | 1 |
| Narumi, K | 1 |
| Furugen, A | 1 |
| Miyoshi, H | 1 |
| Nakamura, A | 1 |
| Yamada, T | 1 |
| Atsumi, T | 1 |
| Iseki, K | 1 |
| Wang, SY | 1 |
| Zhu, S | 1 |
| Wu, J | 3 |
| Zhang, M | 2 |
| Xu, W | 1 |
| Cui, J | 1 |
| Yu, B | 2 |
| Cao, W | 1 |
| Danta, M | 1 |
| Kumar, SS | 3 |
| Liu, Z | 2 |
| Braithwaite, HE | 1 |
| Cheng, TS | 1 |
| Naja, K | 1 |
| El Shamieh, S | 1 |
| Fakhoury, R | 1 |
| Wu, M | 2 |
| Yan, D | 1 |
| Pan, H | 1 |
| Li, F | 1 |
| Ren, M | 1 |
| Xu, M | 1 |
| Broskey, NT | 1 |
| Zou, K | 1 |
| Dohm, GL | 1 |
| Houmard, JA | 1 |
| Rajala, A | 1 |
| Soni, K | 1 |
| Rajala, RVS | 1 |
| Kuan, IHS | 1 |
| Wright, DFB | 1 |
| Duffull, SB | 1 |
| Bozdemir-Ozel, C | 1 |
| Arikan, H | 1 |
| Calik-Kutukcu, E | 1 |
| Karadüz, BN | 1 |
| Inal-Ince, D | 1 |
| Kabakci, G | 1 |
| Sumer, E | 1 |
| Dagdelen, S | 1 |
| Goonoo, MS | 1 |
| Morris, R | 1 |
| Raithatha, A | 1 |
| Creagh, F | 1 |
| Elshafei, MN | 1 |
| Alamin, M | 1 |
| Mohamed, MFH | 1 |
| Ruiz-Ramos, J | 1 |
| Lozano-Polo, L | 1 |
| Juanes-Borrego, A | 1 |
| Agra-Montava, I | 1 |
| Puig-Campmany, M | 1 |
| Mangues-Bafalluy, MA | 1 |
| Modi, A | 1 |
| Wilson, JL | 1 |
| Dobbins, R | 1 |
| Hussey, EK | 1 |
| O'Connor-Semmes, R | 1 |
| Andrews, S | 1 |
| Tao, W | 1 |
| Wilkison, WO | 1 |
| Cheatham, B | 1 |
| Sagar, K | 1 |
| Hanmant, B | 1 |
| Connelly, PJ | 1 |
| Lonergan, M | 1 |
| Soto-Pedre, E | 1 |
| Donnelly, L | 1 |
| Zhou, K | 1 |
| Pearson, ER | 1 |
| Brinkmann, C | 5 |
| Schäfer, L | 1 |
| Masoud, M | 1 |
| Latsch, J | 2 |
| Lay, D | 1 |
| Bloch, W | 5 |
| Brixius, K | 5 |
| Smolders, EJ | 1 |
| Colbers, A | 1 |
| de Kanter, CTMM | 1 |
| Velthoven-Graafland, K | 1 |
| Wolberink, LT | 1 |
| van Ewijk-Beneken Kolmer, N | 1 |
| Drenth, JPH | 1 |
| Aarnoutse, RE | 1 |
| Tack, CJ | 1 |
| Burger, DM | 1 |
| Wang, P | 2 |
| Zhuo, X | 1 |
| Chu, W | 1 |
| Tang, X | 1 |
| Schommers, P | 1 |
| Thurau, A | 1 |
| Bultmann-Mellin, I | 1 |
| Guschlbauer, M | 1 |
| Klatt, AR | 1 |
| Rozman, J | 1 |
| Klingenspor, M | 1 |
| de Angelis, MH | 1 |
| Alber, J | 1 |
| Gründemann, D | 1 |
| Sterner-Kock, A | 1 |
| Wiesner, RJ | 1 |
| Wu, MC | 1 |
| Ye, WR | 1 |
| Zheng, YJ | 1 |
| Zhang, SS | 1 |
| Claus, P | 1 |
| Gimenes, AM | 1 |
| Castro, JR | 1 |
| Mantovani, MM | 1 |
| Kanayama, KK | 1 |
| Simões, DMN | 1 |
| Schwartz, DS | 1 |
| Asano, RY | 1 |
| Browne, RAV | 1 |
| Sales, MM | 2 |
| Arsa, G | 2 |
| Moraes, JFVN | 1 |
| Coelho-Júnior, HJ | 1 |
| Moraes, MR | 1 |
| Oliveira-Silva, I | 1 |
| Atlas, SE | 1 |
| Lewis, JE | 1 |
| Simões, HG | 5 |
| Tan, N | 1 |
| Zhou, Y | 1 |
| Wei, H | 1 |
| Ren, S | 1 |
| Yu, F | 1 |
| Chen, H | 1 |
| Jia, C | 1 |
| Yang, G | 1 |
| Song, Y | 1 |
| Deden, LN | 1 |
| Aarts, EO | 1 |
| Aelfers, SCW | 1 |
| van Borren, MMGJ | 1 |
| Janssen, IMC | 1 |
| Berends, FJ | 1 |
| de Boer, H | 1 |
| Lv, X | 1 |
| Ren, Q | 1 |
| Zhou, L | 1 |
| Geng, Y | 1 |
| Song, J | 1 |
| Mina, A | 1 |
| Puchi, B | 1 |
| Yang, S | 1 |
| Meng, S | 1 |
| Yang, L | 1 |
| Manders, M | 1 |
| van Luin, M | 1 |
| Kramers, C | 1 |
| Bosch, FH | 1 |
| Cohn, A | 1 |
| Ohri, A | 1 |
| Lalau, JD | 3 |
| Kajbaf, F | 2 |
| Bennis, Y | 1 |
| Hurtel-Lemaire, AS | 1 |
| Belpaire, F | 1 |
| De Broe, ME | 1 |
| Rebholz, CM | 1 |
| Zheng, Z | 1 |
| Chang, P | 1 |
| Tin, A | 2 |
| Köttgen, A | 1 |
| Wagenknecht, LE | 1 |
| Coresh, J | 2 |
| Boerwinkle, E | 2 |
| Selvin, E | 2 |
| Mondal, LK | 3 |
| Bhaduri, G | 3 |
| Bhattacharya, B | 4 |
| Ding, X | 1 |
| Lin, S | 1 |
| Weng, H | 1 |
| Liang, J | 1 |
| Novita, BD | 1 |
| Pranoto, A | 1 |
| Soediono, EI | 1 |
| Mertaniasih, NM | 1 |
| Hansen, D | 1 |
| Verboven, K | 1 |
| van Dijk, JW | 1 |
| Zorenc, A | 1 |
| Minten, L | 1 |
| Smeets, K | 1 |
| Verdijk, LB | 1 |
| van Loon, LJC | 1 |
| Francisco, CO | 1 |
| Beltrame, T | 1 |
| Hughson, RL | 1 |
| Milan-Mattos, JC | 1 |
| Ferroli-Fabricio, AM | 1 |
| Galvão Benze, B | 1 |
| Ferraresi, C | 1 |
| Parizotto, NA | 1 |
| Bagnato, VS | 1 |
| Borghi-Silva, A | 1 |
| Porta, A | 1 |
| Catai, AM | 1 |
| Santos, JL | 1 |
| Cataldo, LR | 1 |
| Cortés-Rivera, C | 1 |
| Bravo, C | 1 |
| Díaz-Casanova, L | 1 |
| Martínez, JA | 1 |
| Milagro, FI | 1 |
| Galgani, J | 1 |
| Prabhu, RA | 1 |
| Mareddy, AS | 1 |
| Nagaraju, SP | 1 |
| Rangaswamy, D | 1 |
| Guddattu, V | 1 |
| Zhang, QC | 1 |
| Hastings, C | 1 |
| Johnson, K | 1 |
| Slaven, E | 1 |
| Abdessadek, M | 1 |
| Khabbal, Y | 1 |
| Magoul, R | 1 |
| Marmouzi, I | 1 |
| Ajdi, F | 1 |
| de Sousa, MV | 1 |
| Fukui, R | 1 |
| Dagogo-Jack, S | 1 |
| Krustrup, P | 1 |
| Zouhal, H | 1 |
| da Silva, MER | 1 |
| Sun, X | 1 |
| Meng, Q | 1 |
| Wang, Y | 2 |
| Ma, X | 1 |
| Geng, H | 1 |
| Sun, L | 1 |
| Kalantar-Zadeh, K | 1 |
| Uppot, RN | 1 |
| Lewandrowski, KB | 1 |
| Lee, C | 1 |
| Choi, JS | 1 |
| Kim, I | 1 |
| Oh, KT | 2 |
| Lee, ES | 2 |
| Park, ES | 2 |
| Lee, KC | 3 |
| Youn, YS | 2 |
| Qi, F | 1 |
| Fan, Q | 1 |
| He, F | 1 |
| Tian, G | 1 |
| Yang, T | 1 |
| Ma, G | 1 |
| Su, Z | 1 |
| Juraschek, SP | 2 |
| Miller, ER | 2 |
| Brancati, FL | 4 |
| Young, JH | 5 |
| Badeau, RM | 1 |
| Honka, MJ | 1 |
| Lautamäki, R | 1 |
| Stewart, M | 1 |
| Kangas, AJ | 1 |
| Soininen, P | 1 |
| Ala-Korpela, M | 1 |
| Nuutila, P | 2 |
| Ciechanowska, A | 2 |
| Ladyzynski, P | 2 |
| Wojcicki, JM | 2 |
| Sabalinska, S | 2 |
| Krzymien, J | 2 |
| Pulawska, E | 2 |
| Karnafel, W | 2 |
| Foltynski, P | 2 |
| Kawiak, J | 2 |
| Azzoug, ML | 1 |
| Briet, C | 1 |
| Desailloud, R | 1 |
| Al-Hwiesh, AK | 1 |
| Abdul-Rahman, IS | 1 |
| El-Deen, MA | 1 |
| Larbi, E | 1 |
| Divino-Filho, JC | 1 |
| Al-Mohanna, FA | 1 |
| Gupta, KL | 1 |
| Eppenga, WL | 1 |
| Lalmohamed, A | 1 |
| Geerts, AF | 1 |
| Derijks, HJ | 1 |
| Wensing, M | 1 |
| Egberts, A | 1 |
| De Smet, PA | 1 |
| de Vries, F | 1 |
| Madiraju, AK | 1 |
| Erion, DM | 1 |
| Rahimi, Y | 1 |
| Zhang, XM | 1 |
| Braddock, DT | 1 |
| Albright, RA | 1 |
| Prigaro, BJ | 1 |
| Wood, JL | 1 |
| Bhanot, S | 1 |
| MacDonald, MJ | 1 |
| Jurczak, MJ | 1 |
| Camporez, JP | 1 |
| Lee, HY | 1 |
| Cline, GW | 1 |
| Samuel, VT | 1 |
| Kibbey, RG | 1 |
| Shulman, GI | 1 |
| Naunton, M | 1 |
| Kyle, G | 1 |
| Owoka, F | 1 |
| Naunton-Boom, K | 1 |
| Opitz, D | 2 |
| Lenzen, E | 2 |
| Schiffer, T | 1 |
| Hermann, R | 2 |
| Hellmich, M | 2 |
| Miyamoto, T | 2 |
| Fukuda, K | 2 |
| Watanabe, K | 2 |
| Hidaka, M | 1 |
| Moritani, T | 2 |
| Duong, JK | 2 |
| Furlong, TJ | 2 |
| Kirkpatrick, CM | 2 |
| Ferrannini, E | 2 |
| Lim, SM | 1 |
| Eom, HN | 1 |
| Jiang, HH | 1 |
| Sohn, M | 1 |
| Zhou, A | 1 |
| Ni, J | 1 |
| Xu, Z | 1 |
| Wu, W | 1 |
| Lu, S | 1 |
| Karakousis, PC | 1 |
| Yao, YF | 1 |
| LaRue, S | 1 |
| Malloy, J | 1 |
| Hanatani, T | 1 |
| Sai, K | 1 |
| Tohkin, M | 1 |
| Segawa, K | 1 |
| Saito, Y | 1 |
| Opiolka, A | 1 |
| Redmann, M | 1 |
| Decker, SO | 1 |
| Wortmann, M | 1 |
| Siegler, BH | 1 |
| Ulrich, A | 1 |
| Hofer, S | 1 |
| Brenner, T | 1 |
| Hitchings, AW | 1 |
| Archer, JR | 1 |
| Srivastava, SA | 1 |
| Baker, EH | 1 |
| Chou, CK | 1 |
| Lee, YT | 1 |
| Chen, SM | 1 |
| Hsieh, CW | 1 |
| Huang, TC | 1 |
| Li, YC | 1 |
| Lee, JA | 1 |
| Williams, RS | 1 |
| Heilbronn, LK | 1 |
| Chen, DL | 1 |
| Coster, AC | 1 |
| Samocha-Bonet, D | 1 |
| Balakrishnan, P | 1 |
| Beaty, TH | 1 |
| Hoogeveen, RC | 4 |
| Kao, WH | 1 |
| Keltanen, T | 1 |
| Nenonen, T | 1 |
| Ketola, RA | 1 |
| Ojanperä, I | 1 |
| Sajantila, A | 1 |
| Lindroos, K | 1 |
| Mansor, LS | 1 |
| Mehta, K | 1 |
| Aksentijevic, D | 1 |
| Carr, CA | 1 |
| Lund, T | 1 |
| Cole, MA | 1 |
| Le Page, L | 1 |
| Sousa Fialho, Mda L | 1 |
| Shattock, MJ | 1 |
| Aasum, E | 2 |
| Clarke, K | 1 |
| Tyler, DJ | 1 |
| Heather, LC | 1 |
| López-Soldado, I | 1 |
| Niisuke, K | 1 |
| Veiga, C | 1 |
| Adrover, A | 1 |
| Manzano, A | 1 |
| Martínez-Redondo, V | 1 |
| Camps, M | 1 |
| Bartrons, R | 1 |
| Zorzano, A | 1 |
| Gumà, A | 1 |
| Tricò, D | 1 |
| Baldi, S | 2 |
| Frascerra, S | 1 |
| Venturi, E | 1 |
| Marraccini, P | 1 |
| Neglia, D | 2 |
| Natali, A | 1 |
| Rühl, E | 1 |
| Kerzel, H | 1 |
| Reinhardt, L | 1 |
| Grau, M | 1 |
| Kohl-Bareis, M | 1 |
| Boucaud-Maitre, D | 1 |
| Ropers, J | 1 |
| Porokhov, B | 1 |
| Altman, JJ | 1 |
| Bouhanick, B | 1 |
| Doucet, J | 1 |
| Girardin, E | 1 |
| Kaloustian, E | 1 |
| Lassmann Vague, V | 1 |
| Emmerich, J | 1 |
| Ye, W | 1 |
| Zheng, Y | 1 |
| Zhang, S | 1 |
| Yan, L | 1 |
| Cheng, H | 1 |
| Schwarz, P | 1 |
| Lepelley, M | 1 |
| Giai, J | 1 |
| Yahiaoui, N | 1 |
| Chanoine, S | 1 |
| Villier, C | 1 |
| Menni, C | 1 |
| Migaud, M | 1 |
| Glastonbury, CA | 1 |
| Beaumont, M | 1 |
| Nikolaou, A | 1 |
| Small, KS | 1 |
| Brosnan, MJ | 1 |
| Mohney, RP | 1 |
| Spector, TD | 1 |
| Valdes, AM | 1 |
| Omar, A | 1 |
| Ellen, R | 1 |
| Sorisky, A | 1 |
| Masania, J | 1 |
| Malczewska-Malec, M | 1 |
| Razny, U | 1 |
| Goralska, J | 1 |
| Zdzienicka, A | 1 |
| Kiec-Wilk, B | 1 |
| Gruca, A | 1 |
| Stancel-Mozwillo, J | 1 |
| Dembinska-Kiec, A | 1 |
| Rabbani, N | 1 |
| Thornalley, PJ | 3 |
| Williams, GR | 1 |
| Branford-White, C | 1 |
| Li, H | 1 |
| Zhu, LM | 1 |
| Comar, JF | 1 |
| de Oliveira, DS | 1 |
| Bracht, L | 1 |
| Kemmelmeier, FS | 1 |
| Peralta, RM | 1 |
| Bracht, A | 1 |
| Simsek, IB | 1 |
| Artunay, O | 1 |
| Yokoyama, S | 1 |
| Tsuji, H | 1 |
| Hiraoka, S | 1 |
| Nishihara, M | 1 |
| Lee, EY | 1 |
| Hwang, S | 1 |
| Lee, YH | 1 |
| Lee, SH | 1 |
| Lee, YM | 2 |
| Kang, HP | 1 |
| Han, E | 1 |
| Lee, W | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Cha, BS | 1 |
| Lee, HC | 1 |
| Heden, TD | 1 |
| Liu, Y | 1 |
| Kanaley, JA | 1 |
| Moreira, SR | 4 |
| Oliveira, HB | 1 |
| Lima, LC | 1 |
| Campbell, CS | 4 |
| Baidya, KP | 2 |
| Bandyopadhyay, R | 1 |
| Akki, A | 1 |
| Seymour, AM | 2 |
| Bokhari, S | 1 |
| Emerson, P | 1 |
| Israelian, Z | 1 |
| Gupta, A | 1 |
| Meyer, C | 3 |
| Szabó, Z | 2 |
| Andersson, RG | 1 |
| Arnqvist, HJ | 1 |
| Mogensen, M | 1 |
| Vind, BF | 1 |
| Højlund, K | 1 |
| Beck-Nielsen, H | 6 |
| Sahlin, K | 1 |
| Bao, Y | 1 |
| Zhao, T | 1 |
| Qiu, Y | 1 |
| Su, M | 1 |
| Jia, W | 3 |
| Yoshida, T | 2 |
| Okuno, A | 2 |
| Tanaka, J | 1 |
| Takahashi, K | 2 |
| Nakashima, R | 1 |
| Kanda, S | 2 |
| Ogawa, J | 2 |
| Hagisawa, Y | 2 |
| Fujiwara, T | 2 |
| Philbrick, AM | 1 |
| Ernst, ME | 1 |
| McDanel, DL | 1 |
| Ross, MB | 1 |
| Moores, KG | 1 |
| Liu, F | 3 |
| Lu, JX | 1 |
| Tang, JL | 2 |
| Li, L | 1 |
| Lu, HJ | 2 |
| Hou, XH | 1 |
| Jia, WP | 2 |
| Xiang, KS | 1 |
| Salpeter, SR | 2 |
| Greyber, E | 2 |
| Pasternak, GA | 2 |
| Salpeter Posthumous, EE | 1 |
| Li, Q | 2 |
| Zheng, TS | 1 |
| van Dyken, R | 1 |
| Hubold, C | 1 |
| Meier, S | 1 |
| Hitze, B | 1 |
| Marxsen, A | 1 |
| Oltmanns, KM | 1 |
| Schweiger, U | 1 |
| Lehnert, H | 1 |
| Pellerin, L | 1 |
| Peters, A | 1 |
| Jones, HB | 1 |
| Nugent, D | 1 |
| Jenkins, R | 1 |
| Salpeter, EE | 1 |
| Dela, F | 3 |
| Stallknecht, B | 2 |
| Yu, M | 1 |
| Hui, XM | 1 |
| Zhang, N | 1 |
| Zhang, HP | 1 |
| Song, YL | 1 |
| Crawford, SO | 2 |
| Astor, BC | 2 |
| Ballantyne, CM | 3 |
| Schmidt, MI | 3 |
| Jain, S | 1 |
| Saraf, S | 1 |
| Contarteze, RV | 1 |
| de Alencar Mota, CS | 1 |
| de Oliveira, CA | 1 |
| de Almeida Leme, JA | 1 |
| Bottcher, LB | 1 |
| de Mello, MA | 1 |
| Luciano, E | 1 |
| Ozsari, L | 1 |
| Karadurmus, N | 1 |
| Sahin, M | 1 |
| Uckaya, G | 1 |
| Ural, AU | 1 |
| Kutlu, M | 1 |
| Kristiansen, SB | 2 |
| Løfgren, B | 1 |
| Nielsen, JM | 1 |
| Støttrup, NB | 2 |
| Buhl, ES | 1 |
| Nielsen-Kudsk, JE | 1 |
| Nielsen, TT | 1 |
| Rungby, J | 1 |
| Flyvbjerg, A | 1 |
| Bøtker, HE | 2 |
| Chen, HS | 1 |
| Lin, YC | 1 |
| Lin, LY | 1 |
| Wang, HF | 1 |
| Lin, HD | 1 |
| Morais, PK | 1 |
| Motta, DF | 2 |
| Cunha, VN | 1 |
| Benford, RE | 2 |
| Hiyane, WC | 1 |
| Madrid, B | 1 |
| Prada, FA | 1 |
| de Oliveira, RJ | 1 |
| Nakamura, FY | 1 |
| Löffler, M | 1 |
| Zieker, D | 1 |
| Weinreich, J | 1 |
| Löb, S | 1 |
| Königsrainer, I | 1 |
| Symons, S | 1 |
| Bühler, S | 1 |
| Königsrainer, A | 1 |
| Northoff, H | 1 |
| Beckert, S | 1 |
| Soyoral, YU | 1 |
| Begenik, H | 1 |
| Emre, H | 1 |
| Aytemiz, E | 1 |
| Ozturk, M | 1 |
| Erkoc, R | 1 |
| Kim, H | 1 |
| Lee, J | 1 |
| Kim, TH | 1 |
| Lee, DH | 1 |
| Bae, YH | 1 |
| van Berlo-van de Laar, IR | 1 |
| Vermeij, CG | 1 |
| Doorenbos, CJ | 1 |
| DeYoung, MB | 1 |
| MacConell, L | 1 |
| Sarin, V | 1 |
| Trautmann, M | 1 |
| Herbert, P | 1 |
| Højbjerre, L | 1 |
| Alibegovic, AC | 1 |
| Sonne, MP | 1 |
| Vaag, A | 5 |
| Bruun, JM | 1 |
| Simões, GC | 1 |
| Moraes, JF | 1 |
| Sickmann, HM | 1 |
| Waagepetersen, HS | 1 |
| Schousboe, A | 1 |
| Benie, AJ | 1 |
| Bouman, SD | 1 |
| Mackenzie, R | 1 |
| Maxwell, N | 1 |
| Castle, P | 1 |
| Elliott, B | 1 |
| Brickley, G | 1 |
| Watt, P | 1 |
| Kimura, T | 1 |
| Matsubara, Y | 1 |
| Tsuda, K | 1 |
| Scheijen, JL | 1 |
| Hanssen, NM | 1 |
| van de Waarenburg, MP | 1 |
| Jonkers, DM | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Shen, Y | 1 |
| Tang, J | 1 |
| Zheng, T | 1 |
| Lu, F | 1 |
| Lu, H | 1 |
| Roberts, DM | 1 |
| Choudhuri, S | 1 |
| Mandal, LK | 1 |
| Paine, SK | 1 |
| Dutta, D | 1 |
| Chowdhury, IH | 1 |
| Mukherjee, A | 1 |
| Saha, A | 1 |
| Bhadhuri, G | 1 |
| Jensen, RV | 1 |
| Corkey, BE | 1 |
| Shirihai, O | 1 |
| Mongraw-Chaffin, ML | 1 |
| Matsushita, K | 1 |
| Xu, J | 1 |
| Liu, C | 1 |
| Cai, S | 1 |
| Dong, J | 1 |
| Li, X | 1 |
| Feng, J | 1 |
| Chen, Z | 1 |
| Li, K | 1 |
| Yu, L | 1 |
| Chen, Q | 1 |
| Ding, J | 1 |
| Shantha, GP | 1 |
| Chu, AY | 1 |
| Guallar, E | 1 |
| Pankow, JS | 1 |
| Matsuda, M | 1 |
| Defronzo, RA | 5 |
| Glass, L | 1 |
| Consoli, A | 2 |
| Giordano, M | 1 |
| Bressler, P | 1 |
| Delprato, S | 1 |
| Carey, PE | 2 |
| Halliday, J | 1 |
| Snaar, JE | 2 |
| Morris, PG | 2 |
| Taylor, R | 2 |
| Khan, JK | 1 |
| Pallaki, M | 1 |
| Tolbert, SR | 1 |
| Hornick, TR | 1 |
| Lee, TM | 1 |
| Chou, TF | 1 |
| Selak, MA | 1 |
| Storey, BT | 1 |
| Peterside, I | 1 |
| Simmons, RA | 1 |
| Iozzo, P | 1 |
| Hallsten, K | 1 |
| Oikonen, V | 1 |
| Virtanen, KA | 1 |
| Kemppainen, J | 1 |
| Solin, O | 1 |
| Knuuti, J | 1 |
| Pertek, JP | 1 |
| Vidal, S | 1 |
| Mariot, J | 1 |
| Galy-Floc'h, M | 1 |
| Azoulay, E | 1 |
| Orban, JC | 1 |
| Giunti, C | 1 |
| Levraut, J | 1 |
| Grimaud, D | 1 |
| Ichai, C | 1 |
| Juel, C | 1 |
| Holten, MK | 1 |
| Malaisse, WJ | 4 |
| Ladriere, L | 2 |
| Verbruggen, I | 2 |
| Willem, R | 2 |
| Choi, S | 1 |
| Baudys, M | 1 |
| Kim, SW | 2 |
| Taguchi, T | 1 |
| Yamashita, E | 1 |
| Mizutani, T | 1 |
| Nakajima, H | 1 |
| Yabuuchi, M | 1 |
| Asano, N | 1 |
| Miwa, I | 1 |
| Ravikumar, B | 1 |
| Deelchand, DK | 1 |
| Cook, DB | 1 |
| Neely, RD | 1 |
| English, PT | 1 |
| Firbank, MJ | 1 |
| Lloyd, SG | 1 |
| Zeng, H | 1 |
| Bonen, A | 1 |
| Chatham, JC | 2 |
| Brunetti, P | 2 |
| Pagano, G | 1 |
| Turco, C | 1 |
| Gori, M | 1 |
| Perriello, G | 2 |
| Lee, WJ | 1 |
| Song, KH | 1 |
| Koh, EH | 1 |
| Won, JC | 1 |
| Kim, HS | 1 |
| Park, HS | 1 |
| Kim, MS | 1 |
| Lee, KU | 1 |
| Park, JY | 1 |
| Baker, DJ | 2 |
| Timmons, JA | 2 |
| Greenhaff, PL | 2 |
| Metz, L | 1 |
| Sirvent, P | 1 |
| Py, G | 1 |
| Brun, JF | 1 |
| Fédou, C | 1 |
| Raynaud, E | 1 |
| Mercier, J | 1 |
| Woerle, HJ | 1 |
| Szoke, E | 1 |
| Dostou, JM | 1 |
| Wittlin, SD | 1 |
| Gosmanov, NR | 1 |
| Welle, SL | 1 |
| Gerich, JE | 2 |
| Lango, R | 1 |
| Smoleński, RT | 1 |
| Rogowski, J | 1 |
| Siebert, J | 1 |
| Wujtewicz, M | 1 |
| Słomińska, EM | 1 |
| Lysiak-Szydłowska, W | 1 |
| Yacoub, MH | 1 |
| Holstein, A | 1 |
| Stumvoll, M | 3 |
| Oakes, ND | 1 |
| Thalén, P | 1 |
| Edgley, A | 1 |
| Larsen, T | 1 |
| Furler, SM | 1 |
| Ljung, B | 1 |
| Severson, D | 1 |
| Eid, A | 1 |
| Bodin, S | 1 |
| Ferrier, B | 1 |
| Delage, H | 1 |
| Boghossian, M | 1 |
| Martin, M | 1 |
| Baverel, G | 1 |
| Conjard, A | 1 |
| Giri, A | 1 |
| Boschmann, M | 1 |
| Kreuzberg, U | 1 |
| Engeli, S | 1 |
| Adams, F | 1 |
| Franke, G | 1 |
| Klaua, S | 1 |
| Scholze, J | 1 |
| Weidinger, G | 1 |
| Luft, FC | 1 |
| Sharma, AM | 1 |
| Jordan, J | 1 |
| van Poelje, PD | 1 |
| Potter, SC | 1 |
| Chandramouli, VC | 1 |
| Landau, BR | 2 |
| Dang, Q | 1 |
| Erion, MD | 1 |
| MacInnes, A | 1 |
| Gaster, M | 1 |
| Lim, VC | 1 |
| Sum, CF | 1 |
| Chan, ES | 1 |
| Yeoh, LY | 1 |
| L'Abbate, A | 1 |
| Vecoli, C | 1 |
| Novelli, M | 1 |
| Ottaviano, V | 1 |
| Barsacchi, R | 1 |
| Paolicchi, A | 1 |
| Masiello, P | 1 |
| Drummond, GS | 1 |
| McClung, JA | 1 |
| Abraham, NG | 1 |
| Yin, J | 1 |
| Gao, Z | 1 |
| Liu, D | 1 |
| Ye, J | 1 |
| Hong, Y | 1 |
| Rohatagi, S | 1 |
| Habtemariam, B | 1 |
| Walker, JR | 1 |
| Schwartz, SL | 1 |
| Mager, DE | 1 |
| Jones, GR | 1 |
| Lazarus, JH | 1 |
| Davies, CJ | 1 |
| Greenwood, RH | 1 |
| Jansson, PA | 2 |
| Smith, U | 2 |
| Lönnroth, P | 4 |
| Goodman, AM | 1 |
| Nurjhan, N | 1 |
| Dailey, G | 1 |
| Féry, F | 1 |
| Balasse, EO | 1 |
| Kelley, D | 1 |
| Mokan, M | 1 |
| Veneman, T | 1 |
| Lao, B | 1 |
| Czyzyk, A | 1 |
| Szutowski, M | 1 |
| Szczepanik, Z | 1 |
| McLellan, AC | 2 |
| Benn, J | 1 |
| Sonksen, PH | 1 |
| Patel, JC | 2 |
| Sawant, MS | 2 |
| Worm, D | 1 |
| Henriksen, JE | 2 |
| Thye-Rønn, P | 1 |
| Melander, A | 1 |
| Yoa, RG | 1 |
| Rapin, JR | 1 |
| Wiernsperger, NF | 1 |
| Martinand, A | 1 |
| Belleville, I | 1 |
| Del Prato, S | 3 |
| Bonadonna, RC | 1 |
| Bonora, E | 1 |
| Gulli, G | 1 |
| Solini, A | 1 |
| Shank, M | 1 |
| Bailey, CJ | 1 |
| Avogaro, A | 2 |
| Toffolo, G | 1 |
| Miola, M | 2 |
| Valerio, A | 2 |
| Tiengo, A | 2 |
| Cobelli, C | 1 |
| Gregorio, F | 2 |
| Ambrosi, F | 1 |
| Filipponi, P | 1 |
| Manfrini, S | 1 |
| Testa, I | 1 |
| Korzets, A | 1 |
| Ori, Y | 1 |
| Chagnac, A | 1 |
| Weinstein, T | 1 |
| Halperin, M | 1 |
| Zevin, D | 1 |
| Gafter, U | 1 |
| Yamauchi, A | 1 |
| Amano, K | 1 |
| Ichikawa, Y | 1 |
| Nakamoto, S | 1 |
| Takei, I | 1 |
| Maruyama, H | 1 |
| Kono, N | 1 |
| Saruta, T | 1 |
| del Rey, A | 1 |
| Monge-Arditi, G | 1 |
| Klusman, I | 1 |
| Besedovsky, HO | 1 |
| Turgan, N | 1 |
| Coker, C | 1 |
| Hamulu, F | 1 |
| Elmaci, S | 1 |
| Yilmaz, C | 1 |
| Ersöz, B | 1 |
| Işleğen, C | 1 |
| Cusi, K | 1 |
| Tayek, JA | 1 |
| Katz, J | 1 |
| Crepaldi, C | 1 |
| Pavan, P | 1 |
| Perusicová, J | 1 |
| Cacáková, V | 1 |
| Richtrová, A | 1 |
| Pepper, GM | 1 |
| Schwartz, M | 1 |
| Thompson, RG | 1 |
| Gottlieb, A | 1 |
| Organ, K | 1 |
| Koda, J | 1 |
| Kisicki, J | 1 |
| Kolterman, OG | 1 |
| Nielsen, MF | 1 |
| Wise, S | 1 |
| Dinneen, SF | 1 |
| Schwenk, WF | 1 |
| Basu, A | 2 |
| Rizza, RA | 3 |
| Vauhkonen, I | 1 |
| Niskanen, L | 1 |
| Vanninen, E | 1 |
| Kainulainen, S | 1 |
| Uusitupa, M | 1 |
| Laakso, M | 1 |
| Lazarus, DD | 1 |
| Trimble, LA | 1 |
| Moldawer, LL | 1 |
| Franzetti, I | 1 |
| Paolo, D | 1 |
| Marco, G | 1 |
| Emanuela, M | 1 |
| Elisabetta, Z | 1 |
| Renato, U | 1 |
| Diraison, F | 2 |
| Large, V | 2 |
| Brunengraber, H | 1 |
| Beylot, M | 2 |
| Holmäng, A | 2 |
| Müller, M | 1 |
| Andersson, OK | 1 |
| Gudat, U | 1 |
| Bungert, S | 1 |
| Kemmer, F | 1 |
| Heinemann, L | 1 |
| Ishikawa, Y | 1 |
| Takeno, H | 1 |
| Tani, T | 1 |
| Sato, T | 1 |
| Magata, K | 1 |
| Koga, N | 1 |
| Mitsumoto, Y | 1 |
| Greco, AV | 1 |
| Mingrone, G | 1 |
| Capristo, E | 1 |
| Benedetti, G | 1 |
| De Gaetano, A | 1 |
| Gasbarrini, G | 1 |
| Ling, ZC | 1 |
| Efendic, S | 1 |
| Wibom, R | 1 |
| Abdel-Halim, SM | 1 |
| Ostenson, CG | 1 |
| Khan, A | 1 |
| Iannello, S | 1 |
| Campione, R | 1 |
| Belfiore, F | 1 |
| Regensteiner, JG | 1 |
| Bauer, TA | 1 |
| Reusch, JE | 1 |
| Brandenburg, SL | 1 |
| Sippel, JM | 1 |
| Vogelsong, AM | 1 |
| Smith, S | 1 |
| Wolfel, EE | 1 |
| Eckel, RH | 1 |
| Hiatt, WR | 1 |
| Nadkarni, V | 1 |
| Dostou, J | 1 |
| Mitrakou, A | 1 |
| Gerich, J | 1 |
| Damsbo, P | 2 |
| Hermann, LS | 1 |
| Hother-Nielsen, O | 2 |
| Giacca, A | 1 |
| Groenewoud, Y | 1 |
| Tsui, E | 1 |
| McClean, P | 1 |
| Zinman, B | 1 |
| Beisswenger, PJ | 1 |
| Howell, SK | 1 |
| Touchette, AD | 1 |
| Lal, S | 1 |
| Szwergold, BS | 1 |
| Malaisse-Lagae, F | 1 |
| Rasmussen, BM | 2 |
| Christiansen, C | 1 |
| Rasmussen, OW | 1 |
| Hansen, C | 1 |
| Hermansen, K | 2 |
| Svedman, C | 1 |
| Samra, JS | 1 |
| Clark, ML | 1 |
| Levy, JC | 1 |
| Frayn, KN | 1 |
| Basu, R | 1 |
| Nielsen, M | 1 |
| Shah, P | 1 |
| Alford, F | 1 |
| Handberg, A | 1 |
| Maugeais, C | 1 |
| Krempf, M | 1 |
| Seoane, J | 1 |
| Barberà, A | 1 |
| Télémaque-Potts, S | 1 |
| Newgard, CB | 1 |
| Guinovart, JJ | 1 |
| Balasubramanyam, A | 1 |
| McKay, S | 1 |
| Nadkarni, P | 1 |
| Rajan, AS | 1 |
| Garza, A | 1 |
| Pavlik, V | 1 |
| Herd, JA | 1 |
| Jahoor, F | 1 |
| Reeds, PJ | 1 |
| Race, JM | 1 |
| Axelsen, M | 1 |
| Lenner, RA | 1 |
| Taskinen, MR | 2 |
| Cancelas, J | 1 |
| Acitores, A | 1 |
| Villanueva-Penacarrillo, ML | 1 |
| Valverde, I | 1 |
| Fosgerau, K | 2 |
| Westergaard, N | 2 |
| Quistorff, B | 1 |
| Grunnet, N | 1 |
| Kristiansen, M | 1 |
| Lundgren, K | 1 |
| Sjöstrand, M | 1 |
| Strindberg, L | 1 |
| Amin, BM | 1 |
| Jagasia, D | 1 |
| Whiting, JM | 1 |
| Concato, J | 1 |
| Pfau, S | 1 |
| McNulty, PH | 1 |
| Orskov, L | 1 |
| Schmitz, O | 2 |
| Arnqvist, H | 1 |
| Håkanson, E | 1 |
| Jorfeldt, L | 1 |
| Svedjeholm, R | 1 |
| Hemmerling, TM | 1 |
| Schmid, MC | 1 |
| Schmidt, J | 1 |
| Kern, S | 1 |
| Jacobi, KE | 1 |
| van der Merwe, MT | 1 |
| Schlaphoff, GP | 1 |
| Crowther, NJ | 1 |
| Boyd, IH | 1 |
| Gray, IP | 1 |
| Joffe, BI | 1 |
| Lönnroth, PN | 1 |
| Davis, TM | 1 |
| Jackson, D | 1 |
| Davis, WA | 1 |
| Bruce, DG | 1 |
| Chubb, P | 1 |
| Sandqvist, MM | 1 |
| Eriksson, JW | 1 |
| Terekhina, NA | 1 |
| Nenasheva, OIu | 1 |
| Akimov, PA | 1 |
| Giroix, MH | 1 |
| Nadi, AB | 1 |
| Sener, A | 1 |
| Portha, B | 1 |
| Khandoudi, N | 1 |
| Delerive, P | 1 |
| Berrebi-Bertrand, I | 1 |
| Buckingham, RE | 1 |
| Staels, B | 1 |
| Bril, A | 1 |
| Breinholt, J | 1 |
| McCormack, JG | 1 |
| Phillips, SA | 1 |
| Velussi, M | 1 |
| Cernigoi, AM | 1 |
| Viezzoli, L | 1 |
| Caffau, C | 1 |
| Segal, KR | 1 |
| Blando, L | 1 |
| Ginsberg-Fellner, F | 1 |
| Edaño, A | 1 |
| Osei, K | 1 |
| Cottrell, DA | 1 |
| Bossetti, B | 1 |
| Skött, P | 1 |
| Gall, MA | 1 |
| Puhakainen, I | 1 |
| Koivisto, VA | 1 |
| Yki-Järvinen, H | 2 |
| Ravanam, A | 1 |
| Jeffery, J | 1 |
| Nehlawi, M | 1 |
| Abraira, C | 2 |
| Ratheiser, K | 1 |
| Schneeweiss, B | 1 |
| Waldhäusl, W | 1 |
| Fasching, P | 1 |
| Korn, A | 1 |
| Nowotny, P | 1 |
| Rohac, M | 1 |
| Wolf, HP | 1 |
| Barzilai, N | 1 |
| Simonson, DC | 1 |
| Marchetti, P | 2 |
| Benzi, L | 1 |
| Giannarelli, R | 2 |
| Cecchetti, P | 1 |
| Villani, G | 1 |
| Di Cianni, G | 1 |
| Di Carlo, A | 1 |
| Navalesi, R | 2 |
| Blagosklonnaia, IaV | 1 |
| Krasil'nikova, EI | 1 |
| Zaĭed, N | 1 |
| Babenko, AIu | 1 |
| Thorburn, AW | 1 |
| Gumbiner, B | 1 |
| Bulacan, F | 1 |
| Wallace, P | 1 |
| Henry, RR | 1 |
| Hepp, KD | 1 |
| Bauersachs, R | 1 |
| Piwernetz, K | 1 |
| Renner, R | 1 |
| Karl, IE | 1 |
| Gavin, JR | 1 |
| Levy, J | 1 |
| Chandalia, HB | 1 |
| Rangnath, M | 1 |
| Lovejoy, J | 1 |
| Mellen, B | 1 |
| Digirolamo, M | 1 |
| Sabino, F | 1 |
| DiCarlo, A | 1 |
| Cicchetti, V | 1 |
| Boivin, M | 1 |
| Flourie, B | 1 |
| Go, VL | 1 |
| DiMagno, EP | 1 |
| Akanji, AO | 1 |
| Humphreys, S | 1 |
| Thursfield, V | 1 |
| Hockaday, TD | 1 |
| Andersen, PH | 1 |
| Pedersen, O | 1 |
| Sane, T | 1 |
| Helve, E | 1 |
| Karonen, SL | 1 |
| Nikkilä, EA | 1 |
| Capaldo, B | 1 |
| Santoro, D | 1 |
| Riccardi, G | 1 |
| Perrotti, N | 1 |
| Saccà, L | 1 |
| Monge, L | 1 |
| Mojena, M | 1 |
| Ortega, JL | 1 |
| Samper, B | 1 |
| Cabello, MA | 1 |
| Feliu, JE | 1 |
| Schneider, SH | 1 |
| Khachadurian, AK | 1 |
| Amorosa, LF | 1 |
| Gavras, H | 1 |
| Fineberg, SE | 1 |
| Ruderman, NB | 1 |
| Reich, A | 1 |
| Brunken, R | 1 |
| Soneru, I | 1 |
| Jackson, RA | 1 |
| Hawa, MI | 1 |
| Jaspan, JB | 1 |
| Sim, BM | 1 |
| Disilvio, L | 1 |
| Featherbe, D | 1 |
| Kurtz, AB | 1 |
| Cheli, V | 1 |
| Buzzo, P | 1 |
| Melga, P | 1 |
| Accoto, S | 1 |
| Prando, R | 1 |
| Thomas, DJ | 1 |
| Platt, HS | 1 |
| Alberti, KG | 1 |
| Yang, DP | 1 |
| Liang, JZ | 1 |
| Luo, ZT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Metformin Overdose in Adult Patients Treated at the University Hospital of Nancy: Single-center Descriptive Retrospective Observational Study[NCT04762966] | 50 participants (Anticipated) | Observational | 2021-03-01 | Recruiting | |||
| A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered With Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects With Type 2 Diabetes Mellitus[NCT00519480] | Phase 1 | 50 participants (Actual) | Interventional | 2007-09-11 | Completed | ||
| A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers[NCT02565862] | Phase 1 | 20 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Alkaline Diet for Insulin Sensitivity[NCT02501343] | 32 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Effect of Adding Metformin to Insulin in Uncontrolled Diabetic Patients During the 3rd Trimester of Pregnancy on Glycemic Control, Fetal and Neonatal Outcomes ,Randomized Controlled Trial[NCT05479214] | Phase 4 | 150 participants (Actual) | Interventional | 2022-07-29 | Completed | ||
| Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I[NCT03445702] | Early Phase 1 | 15 participants (Actual) | Interventional | 2018-10-15 | Completed | ||
| Is There Any Effect of Maternal Dietary Acid Load During Pregnancy on Arising Gestational Diabetes Mellitus?[NCT03790579] | 80 participants (Actual) | Observational | 2014-01-05 | Completed | |||
| Abnormal Glucose Tolerance is Associated With a Reduced Myocardial Metabolic Flexibility in Patients With Dilated Cardiomyopathy[NCT02440217] | 15 participants (Anticipated) | Observational | 2015-05-31 | Enrolling by invitation | |||
| Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery[NCT04284722] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-02-29 | Not yet recruiting | ||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial[NCT03980990] | Phase 4 | 500 participants (Anticipated) | Interventional | 2019-06-17 | Recruiting | ||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| The Relation Between Acute Changes in the Systemic Inflammatory Response, Thiamine and Magnesium Concentrations and Transketolase Activity After Elective Knee Arthroplasty.[NCT03554668] | 47 participants (Actual) | Observational | 2018-01-15 | Completed | |||
| Evaluation of the Effects of Electrical Muscle Stimulation on Carbohydrate Homeostasis in Adult Patients With Obesity[NCT04643899] | 60 participants (Actual) | Interventional | 2021-03-29 | Completed | |||
| A Randomised Controlled Trial of the Effect of Remote Ischaemic Conditioning on Coronary Endothelial Function in Patients With Angina.[NCT02666235] | Phase 2 | 60 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Gastric Tolerability and Pharmacokinetics of an Extended Release Metformin and an Immediate Release Metformin[NCT00941239] | Phase 1 | 24 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance[NCT02045290] | Phase 3 | 37 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
13 reviews available for lactic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Carriers; Humans; Insulin; | 2023 |
Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; La | 2022 |
High risk and low prevalence diseases: Metformin toxicities.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactic Acid; Metformin; Pr | 2023 |
Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis.
Topics: Acidosis; Diabetes Mellitus, Type 2; Drug Monitoring; Humans; Hypoglycemic Agents; Kidney; Kidney Di | 2019 |
Plasma Lactate as a Marker for Metabolic Health.
Topics: Biomarkers; Citric Acid Cycle; Diabetes Mellitus, Type 2; Fasting; Humans; Lactic Acid; Metabolic Sy | 2020 |
Osmolar-gap in the setting of metformin-associated lactic acidosis: Case report and a literature review highlighting an apparently unusual association.
Topics: Acid-Base Imbalance; Acidosis, Lactic; Acute Kidney Injury; Diabetes Mellitus, Type 2; Humans; Hypog | 2020 |
Exercise during short-term exposure to hypoxia or hyperoxia - novel treatment strategies for type 2 diabetic patients?!
Topics: Diabetes Mellitus, Type 2; Exercise Therapy; Glucose; Humans; Hyperoxia; Hypoxia; Insulin Resistance | 2018 |
[Metformin-associated lactic acidosis: an insufficiently recognised problem].
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2017 |
Dicarbonyl stress in clinical obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Lactic Acid; Lactoylglutathione Lyase; Mice; Non-alcohol | 2016 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Cohort Studies; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2010 |
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; H | 2011 |
Metformin and intestinal glucose handling.
Topics: Acidosis, Lactic; Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Intestin | 1995 |
40 trials available for lactic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interacti | 2021 |
Effects of Cycling and Exergaming on Neurotrophic Factors in Elderly Type 2 Diabetic Men - A Preliminary Investigation.
Topics: Aged; Bicycling; Cross-Over Studies; Diabetes Mellitus, Type 2; Exercise; Humans; Lactic Acid; Male; | 2017 |
Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabet | 2017 |
Bradykinin, insulin, and glycemia responses to exercise performed above and below lactate threshold in individuals with type 2 diabetes.
Topics: Aged; Analysis of Variance; Blood Glucose; Bradykinin; Cross-Over Studies; Diabetes Mellitus, Type 2 | 2017 |
A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients.
Topics: Acidosis, Lactic; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lactic Acid | 2018 |
Adipose tissue lipolytic inhibition enhances the glucoregulatory properties of exercise in type 2 diabetes patients.
Topics: Adipose Tissue; Administration, Oral; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; | 2018 |
Effects of light-emitting diode therapy (LEDT) on cardiopulmonary and hemodynamic adjustments during aerobic exercise and glucose levels in patients with diabetes mellitus: A randomized, crossover, double-blind and placebo-controlled clinical trial.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Female; Glucose; Heart | 2019 |
Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female | 2014 |
Abnormal Glucose Tolerance Is Associated with a Reduced Myocardial Metabolic Flexibility in Patients with Dilated Cardiomyopathy.
Topics: Aged; Biomarkers; Blood Flow Velocity; Blood Glucose; Cardiac Pacing, Artificial; Cardiomyopathy, Di | 2016 |
Effects of Wearing Compression Stockings on the Physical Performance of T2DM Men with MetS.
Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Erythrocyte Deformability; Exercise Test; Hemod | 2016 |
Low plasma lactate concentration as a biomarker of an incompetent brain-pull: a risk factor for weight gain in type 2 diabetes patients.
Topics: Adult; Biomarkers; Brain Diseases, Metabolic; Cohort Studies; Diabetes Mellitus, Type 2; Energy Meta | 2010 |
Blood glucose control for individuals with type-2 diabetes: acute effects of resistance exercise of lower cardiovascular-metabolic stress.
Topics: Adipose Tissue; Adult; Area Under Curve; Blood Glucose; Blood Pressure; Cardiovascular System; Diabe | 2012 |
Intermittent exercise with and without hypoxia improves insulin sensitivity in individuals with type 2 diabetes.
Topics: Algorithms; Blood Glucose; Cross-Over Studies; Deuterium; Diabetes Mellitus, Type 2; Exercise; Gluco | 2012 |
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glu | 2002 |
Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dou | 2004 |
Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients.
Topics: Aged; Blood Pressure; Cardiopulmonary Bypass; Cardiotonic Agents; Carnitine; Diabetes Mellitus, Type | 2005 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blo | 2006 |
Microdialysis technique as a monitoring system for acute complications of diabetes.
Topics: Abdominal Fat; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2008 |
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglyc | 2008 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Alcohol tolerance in patients with non-insulin-dependent (type 2) diabetes treated with sulphonylurea derivatives.
Topics: Acetaldehyde; Adult; Aged; Blood Gas Analysis; Blood Glucose; Body Temperature Regulation; Diabetes | 1994 |
Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; | 1994 |
Is metformin safe enough for ageing type 2 diabetic patients?
Topics: Aged; Aged, 80 and over; Aging; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therap | 1996 |
Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gluconeogenesis; Glucose; Gly | 1996 |
Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
Topics: Adult; Amyloid; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gas | 1997 |
Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM.
Topics: Adult; Alanine; Blood Glucose; Carbon Isotopes; Citric Acid; Citric Acid Cycle; Diabetes Mellitus, T | 1998 |
The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exercise; Glucagon; Glyburide; Humans; H | 1998 |
Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus.
Topics: Adult; Autonomic Nervous System; Body Composition; Densitometry; Diabetes Mellitus; Diabetes Mellitu | 1998 |
Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.
Topics: Adult; Blood Glucose; Body Weight; Calorimetry, Indirect; Diabetes Mellitus; Diabetes Mellitus, Type | 1998 |
Metformin reduces systemic methylglyoxal levels in type 2 diabetes.
Topics: Adult; Aged; Deoxyglucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Huma | 1999 |
Alcohol and postexercise metabolic responses in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Eating; Ethanol; Exercise; Fasting; Fatty Acids, Nonesteri | 1999 |
Suppression of nocturnal fatty acid concentrations by bedtime carbohydrate supplement in type 2 diabetes: effects on insulin sensitivity, lipids, and glycemic control.
Topics: Blood Glucose; Body Weight; C-Peptide; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type | 2000 |
Levels of lactic acid, normal level & its relation to food, glucose, cholesterol, raised blood urea and phenformin therapy.
Topics: Diabetes Mellitus, Type 2; Diet; Female; Humans; Hypercholesterolemia; Hyperglycemia; India; Lactic | 2000 |
Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease.
Topics: Angiography; Blood Glucose; Coronary Circulation; Diabetes Mellitus, Type 2; Fasting; Hemodynamics; | 2001 |
Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects.
Topics: Acute Disease; Blood Glucose; Central Nervous System Depressants; Diabetes Mellitus, Type 2; Ethanol | 2001 |
Effects of high-dose glucose-insulin-potassium on myocardial metabolism after coronary surgery in patients with Type II diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Analysis of Variance; Angina Pectoris; Cardiopulmonary Bypass; Catheter | 2001 |
Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, | 2001 |
The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study.
Topics: Aged; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Lactic Acid; Male; Me | 2001 |
Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study.
Topics: Aged; C-Peptide; Cardiotonic Agents; Deoxyepinephrine; Diabetes Mellitus, Type 2; Double-Blind Metho | 1990 |
Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dou | 1989 |
231 other studies available for lactic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Cadmium exposure decreases fasting blood glucose levels and exacerbates type-2 diabetes in a mouse model.
Topics: Animals; Blood Glucose; Cadmium; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease | 2022 |
Moderate l-lactate administration suppresses adipose tissue macrophage M1 polarization to alleviate obesity-associated insulin resistance.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; I | 2022 |
The Role of Lactate Exercise Test and Fasting Plasma C-Peptide Levels in the Diagnosis of Mitochondrial Diabetes: Analysis of Clinical Characteristics of 12 Patients With Mitochondrial Diabetes in a Single Center With Long-Term Follow-Up.
Topics: Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Exercise Test; Fasting; Follow-Up Studies; Humans | 2022 |
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Topics: Acidosis, Lactic; Animals; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Agents; Lactic Acid | 2022 |
Inhibition of basal and glucagon-induced hepatic glucose production by 991 and other pharmacological AMPK activators.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Glucos | 2022 |
An exercise-inducible metabolite that suppresses feeding and obesity.
Topics: Adiposity; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Energy M | 2022 |
Regulatory Effects of Metformin, an Antidiabetic Biguanide Drug, on the Metabolism of Primary Rat Adipocytes.
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Epinephrine; Glucose; Hypoglycemic Agents; Insulin; | 2022 |
Laurolitsine ameliorates type 2 diabetes by regulating the hepatic LKB1-AMPK pathway and gut microbiota.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Aporphines; D | 2022 |
Metformin-associated severe lactic acidosis combined with multi-organ insufficiency induced by infection with Aeromonas veronii: A case report.
Topics: Acidosis, Lactic; Aeromonas veronii; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2023 |
[Use of metformin in patients with type 2 diabetes and acute myocardial infarction: safety and impact on glycemic control].
Topics: Acute Kidney Injury; Diabetes Mellitus, Type 2; Glycemic Control; Humans; Hypoglycemic Agents; Lacti | 2023 |
The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Lact | 2023 |
Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study.
Topics: Asian People; Diabetes Mellitus, Type 2; Humans; Lactic Acid; Metformin; Non-alcoholic Fatty Liver D | 2023 |
Hyperpolarized [1-
Topics: Agmatine; Animals; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Lactic Acid; M | 2023 |
Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Di | 2023 |
pH balance and lactic acid increase in the vitreous body of diabetes mellitus patients.
Topics: Aged; Blood Gas Analysis; Calcium; Carbon Dioxide; Cross-Sectional Studies; Diabetes Mellitus, Type | 2019 |
Laboratory-Confirmed Metformin-Associated Lactic Acidosis
Topics: Acidosis, Lactic; Aged; Alcohol Drinking; Continuous Renal Replacement Therapy; Diabetes Mellitus, T | 2019 |
Dysregulation of Glycogen Metabolism with Concomitant Spatial Memory Dysfunction in Type 2 Diabetes: Potential Beneficial Effects of Chronic Exercise.
Topics: Diabetes Mellitus, Type 2; Exercise; Exercise Therapy; Glycogen; Hippocampus; Humans; Lactic Acid; N | 2019 |
Metformin is associated with increase in lactate level in elderly patients with type 2 diabetes and CKD stage 3: A case-control study.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Neph | 2020 |
Development of Electrochemical Methods to Enzymatically Detect Lactate and Glucose Using Imaginary Impedance for Enhanced Management of Glycemic Compromised Patients.
Topics: Algorithms; Biomarkers; Biosensing Techniques; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2019 |
Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population.
Topics: Aged; Alanine; Diabetes Mellitus, Type 2; DNA; Female; Genetic Variation; Humans; Japan; Lactic Acid | 2020 |
Exercise enhances cardiac function by improving mitochondrial dysfunction and maintaining energy homoeostasis in the development of diabetic cardiomyopathy.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Blood Pressure; Cells, Cultured; Dia | 2020 |
The safety and pharmacokinetics of metformin in patients with chronic liver disease.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Chronic Disease; Comorbidity; Cross-Sectional Stud | 2020 |
rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response.
Topics: Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglyc | 2020 |
Interactions among endotoxin, uric acid, and lactate in relation to the risk of type 2 diabetes: A population-based study.
Topics: Adult; Aged; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Endotoxins; Female; Humans; | 2020 |
Metabolic and Non-metabolic Roles of Pyruvate Kinase M2 Isoform in Diabetic Retinopathy.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 6; Diabetes Mellitus, Type 2; Diabetic Retinopat | 2020 |
Understanding the association between metformin plasma concentrations and lactate.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactic Acid; Metformin | 2021 |
Subclinical Inflammation Is Associated With Reductions in Muscle Oxygenation, Exercise Capacity and Quality of Life in Adults With Type 2 Diabetes.
Topics: Adipose Tissue; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Exercise Test; Exerc | 2020 |
Metformin-associated lactic acidosis: reinforcing learning points.
Topics: Acidosis, Lactic; Acute Kidney Injury; Bicarbonates; Continuous Renal Replacement Therapy; Diabetes | 2020 |
The usefulness of measuring the anion gap in diagnosing metformin-associated lactic acidosis: a case series.
Topics: Acid-Base Equilibrium; Acidosis, Lactic; Aged; Aged, 80 and over; Anions; Cations; Diabetes Mellitus | 2021 |
New skin papules.
Topics: Darier Disease; Diabetes Mellitus, Type 2; Female; Humans; Kidney Failure, Chronic; Lactic Acid; Mid | 2021 |
Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Melli | 2017 |
Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Carriers; Exenatide; Hydrogels; Lactic Acid; Mice; Microsph | 2017 |
Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Energy Metabolism; Glucose; Hypoglycemic Agents; | 2017 |
Oxamate Enhances the Anti-Inflammatory and Insulin-Sensitizing Effects of Metformin in Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabet | 2017 |
Blood lactate concentration in diabetic dogs.
Topics: Animals; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dog Diseases; Do | 2017 |
Delivery of antagomiR204-conjugated gold nanoparticles from PLGA sheets and its implication in promoting osseointegration of titanium implant in type 2 diabetes mellitus.
Topics: Alkaline Phosphatase; Animals; Antagomirs; Bone and Bones; Cell Adhesion; Cell Death; Cell Survival; | 2017 |
Risk of Metformin-Associated Lactic Acidosis (MALA) in Patients After Gastric Bypass Surgery.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Female; Gastric Bypass; Humans; Hypoglycemic Agents; La | 2018 |
Safety of Metformin Therapy in Patients with Type 2 Diabetes Living on an Oxygen-Deficient Plateau, Tibet, China.
Topics: Acidosis, Lactic; Adult; Altitude; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Human | 2018 |
Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report.
Topics: Acarbose; Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobi | 2017 |
Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4.
Topics: Creatinine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin | 2018 |
Serum metabolomic profile of incident diabetes.
Topics: Amino Acids, Branched-Chain; Asparagine; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; | 2018 |
Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus.
Topics: Adult; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retin | 2018 |
Separation and determination of the enantiomers of lactic acid and 2-hydroxyglutaric acid by chiral derivatization combined with gas chromatography and mass spectrometry.
Topics: Animals; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Glutarates; Humans; Lactic | 2018 |
Plasma lactate and leukocyte mitochondrial DNA copy number as biomarkers of insulin sensitivity in non-diabetic women.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; DNA Copy Number Variations; DNA, Mitochondrial; Female | 2019 |
Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3-5: is it significant?
Topics: Acidosis, Lactic; Creatinine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Moni | 2019 |
Metformin-Associated Lactic Acidosis Presenting Like Acute Mesenteric Ischemia.
Topics: Acidosis, Lactic; Creatinine; Diabetes Mellitus, Type 2; Emergency Service, Hospital; Female; Humans | 2019 |
Follow-up of glycemic index before and after Ramadan fasting in type 2 diabetes patients under antidiabetic medications.
Topics: Acidosis, Lactic; Adult; Aged; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Fasting; Female | 2019 |
Biomarkers of insulin action during single soccer sessions before and after a 12-week training period in type 2 diabetes patients on a caloric-restricted diet.
Topics: Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Diet, Reducing; Exerci | 2019 |
Brain metabolite changes in patients with type 2 diabetes and cerebral infarction using proton magnetic resonance spectroscopy.
Topics: Aged; Aspartic Acid; Blood Glucose; Brain; Cerebral Infarction; Choline; Creatine; Diabetes Mellitus | 2014 |
Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion.
Topics: Abdominal Pain; Acidosis, Lactic; Confusion; Diabetes Mellitus, Type 2; Diagnosis, Differential; Fem | 2013 |
Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Topics: Administration, Inhalation; Adsorption; Analysis of Variance; Animals; Blood Glucose; Cell Line; Cel | 2013 |
Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.
Topics: Chemistry, Pharmaceutical; Circular Dichroism; Delayed-Action Preparations; Diabetes Mellitus, Type | 2013 |
Plasma lactate and diabetes risk in 8045 participants of the atherosclerosis risk in communities study.
Topics: Adult; Aged; Atherosclerosis; Biomarkers; Blood Glucose; Community-Based Participatory Research; Dia | 2013 |
Microdialysis monitoring of glucose, lactate, glycerol, and pyruvate in patients with diabetic ketoacidosis.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus | 2013 |
Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Hypersensitivi | 2014 |
Metformin in peritoneal dialysis: a pilot experience.
Topics: Acidosis, Lactic; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin | 2014 |
Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
Topics: Acidosis, Lactic; Adult; Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Human | 2014 |
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycerolphospha | 2014 |
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycerolphospha | 2014 |
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycerolphospha | 2014 |
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycerolphospha | 2014 |
Pharmacist review prevents evolving metformin-associated lactic acidosis.
Topics: Acidosis, Lactic; Aged; Community Pharmacy Services; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2014 |
Endurance training alters skeletal muscle MCT contents in T2DM men.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Humans; Lactic Acid; Male; Middle Aged; Monocarbox | 2014 |
Gender difference in metabolic responses to surface electrical muscle stimulation in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Electric Stimulation; Exercise; Fatty Acids, Noneste | 2015 |
The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus.
Topics: Aged; Australia; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glycated Hemoglobin | 2015 |
The target of metformin in type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Dihydroxyacetone Phosphate; Gluconeogenesis; Glycerolphosphate D | 2014 |
Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Topics: Acylation; Animals; Antibodies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Compoun | 2015 |
Metabolomics specificity of tuberculosis plasma revealed by (1)H NMR spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Community-Acquired Infections; Dia | 2015 |
Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
Topics: Adult; Device Approval; Diabetes Mellitus, Type 2; Drug Administration Schedule; Equipment Design; E | 2015 |
Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients.
Topics: Acidosis, Lactic; Adult; Aged; Cohort Studies; Data Collection; Databases, Factual; Diabetes Mellitu | 2015 |
Endurance training alters basal erythrocyte MCT-1 contents and affects the lactate distribution between plasma and red blood cells in T2DM men following maximal exercise.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Erythrocytes; Exercise; Humans; Insulin Resistance; Lact | 2015 |
[Metformin-induced lactic acidosis : Severe symptoms with difficult diagnostics].
Topics: Acidosis, Lactic; Acute Kidney Injury; Carbon Dioxide; Diabetes Mellitus, Type 2; Epinephrine; Human | 2015 |
Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Biomarkers; Diabetes Mellitus, Type 2; Female; Hum | 2015 |
Elevated urinary D-lactate levels in patients with diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hum | 2015 |
Dietary acid load, metabolic acidosis and insulin resistance - Lessons from cross-sectional and overfeeding studies in humans.
Topics: Acidosis; Acids; Adiposity; Adult; Biomarkers; Blood Glucose; Body Mass Index; Cross-Sectional Studi | 2016 |
GCKR and PPP1R3B identified as genome-wide significant loci for plasma lactate: the Atherosclerosis Risk in Communities (ARIC) study.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Black or African American; Cohort Studies; Diabetes M | 2016 |
Post-mortem analysis of lactate concentration in diabetics and metformin poisonings.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ketone Bodies; Lactic Acid; M | 2015 |
Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation.
Topics: Adaptation, Physiological; Animals; Cell Hypoxia; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathi | 2016 |
Neuregulin improves response to glucose tolerance test in control and diabetic rats.
Topics: Animals; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fructosediphosphates; Gluco | 2016 |
Lactic acidosis: relationship between metformin levels, lactate concentration and mortality.
Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Hum | 2016 |
Oxamate Improves Glycemic Control and Insulin Sensitivity via Inhibition of Tissue Lactate Production in db/db Mice.
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Eating; | 2016 |
[For diabetics sports are more strenuous].
Topics: Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Insulin Resistance; Lactic Acid; Oxygen; Physical | 2016 |
Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Di | 2016 |
Metabolomic profiling to dissect the role of visceral fat in cardiometabolic health.
Topics: Absorptiometry, Photon; Aged; Amino Acids, Branched-Chain; Blood Glucose; Blood Pressure; Body Mass | 2016 |
Metformin-Associated Lactic Acidosis in a Patient with Normal Renal Function.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Female; Humans; Kidney Function Tests; Lactic Aci | 2016 |
Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Melli | 2016 |
The Metabolic Responses to L-Glutamine of Livers from Rats with Diabetes Types 1 and 2.
Topics: Alanine; Ammonia; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gluconeogenesis; Gl | 2016 |
Evaluation of Biochemical Composition of Vitreous of Eyes of Diabetic Patients Using Proton Magnetic Resonance Spectroscopy.
Topics: Adult; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fluorescein An | 2017 |
Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin.
Topics: Adult; Aged; Asian People; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Female; Glyca | 2016 |
Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes.
Topics: Acidosis, Lactic; Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; H | 2017 |
Exercise timing and blood lactate concentrations in individuals with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diet; Female; Humans; Hypoglycemic | 2017 |
Methods to identify the lactate and glucose thresholds during resistance exercise for individuals with type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exercise Test; Humans; Lactic Acid; Male; Mid | 2008 |
Alteration of timing of secretion of vascular endothelial growth factors is responsible for progression of diabetic retinopathy.
Topics: Anaerobic Threshold; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disea | 2008 |
Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy.
Topics: Acyl-CoA Dehydrogenase; Animals; CD36 Antigens; Diabetes Mellitus, Type 2; Dietary Fats; Disease Mod | 2009 |
Metabolic fate of plasma glucose during hyperglycemia in impaired glucose tolerance: evidence for further early defects in the pathogenesis of type 2 diabetes.
Topics: Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glu | 2009 |
Intraoperative muscle and fat metabolism in diabetic patients during coronary artery bypass grafting surgery: a parallel microdialysis and organ balance study.
Topics: Aged; Anesthesia, General; Blood Glucose; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Feasibi | 2009 |
Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training.
Topics: Citrate (si)-Synthase; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; Female; Glucose; Huma | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Ag | 2009 |
Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Topics: Alanine; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Dose-Response Relations | 2009 |
Metformin use in renal dysfunction: is a serum creatinine threshold appropriate?
Topics: Acidosis, Lactic; Creatinine; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney Disease | 2009 |
Relationship of plasma creatinine and lactic acid in type 2 diabetic patients without renal dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2009 |
SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
Topics: Base Sequence; China; Diabetes Mellitus, Type 2; DNA Primers; Humans; Hypoglycemic Agents; Lactic Ac | 2010 |
Variation in characteristics of islets of Langerhans in insulin-resistant, diabetic and non-diabetic-rat strains.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; F | 2010 |
Effect of physical training on insulin secretion and action in skeletal muscle and adipose tissue of first-degree relatives of type 2 diabetic patients.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; C-Peptide; Diabetes Mellitus, Type 2; Exerci | 2010 |
[Effect of sustained release of recombinant rat insulin-like growth factor-1 from poly (lactide-CO-glycolide ) microspheres on bone formation in the peri-implant areas in Goto-Kakizaki rats with type 2 diabetes].
Topics: Animals; Delayed-Action Preparations; Dental Implants; Diabetes Mellitus, Experimental; Diabetes Mel | 2010 |
Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Body Mass Index; Carotid Arteries; Cross-Sectional Studies | 2010 |
Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Body Mass Index; Carotid Arteries; Cross-Sectional Studies | 2010 |
Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Body Mass Index; Carotid Arteries; Cross-Sectional Studies | 2010 |
Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Body Mass Index; Carotid Arteries; Cross-Sectional Studies | 2010 |
Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Chemistry, Pharmaceutical; Delayed-Action | 2009 |
Exercise test and glucose homeostasis in rats treated with alloxan during the neonatal period or fed a high calorie diet.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Biomarkers; Blood Glucose; Diabetes Mellitus, Experim | 2009 |
Comparison of lymphomononuclear cell energy metabolism between healthy, impaired glucose intolerance and type 2 diabetes mellitus patients.
Topics: Aged; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucose | 2010 |
Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Glycogen; Lactic Acid; Male; Myocardial I | 2011 |
Old age may not be a contraindication to the use of metformin.
Topics: Age Factors; Aged; Aged, 80 and over; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglyc | 2010 |
Fasting plasma lactate concentrations in ambulatory elderly patients with type 2 diabetes receiving metformin therapy: a retrospective cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fast | 2010 |
Acute resistance exercise is more effective than aerobic exercise for 24h blood pressure control in type 2 diabetics.
Topics: Bicycling; Blood Pressure; Diabetes Mellitus, Type 2; Exercise; Female; Heart Rate; Humans; Hyperten | 2011 |
Lactate threshold prediction by blood glucose and rating of perceived exertion in people with type 2 diabetes.
Topics: Adult; Aged; Anaerobic Threshold; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Exercise Test; | 2010 |
Wound fluid lactate concentration: a helpful marker for diagnosing soft-tissue infection in diabetic foot ulcers? Preliminary findings.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Biomarkers; Body Fluids; Diabetes Mellitus, Ty | 2011 |
Contributions of hepatic gluconeogenesis suppression and compensative glycogenolysis on the glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, in non-obese type 2 diabetes Goto-Kakizaki rats.
Topics: Alanine; Amides; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Fa | 2011 |
Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases.
Topics: Acidosis, Lactic; Adolescent; Bicarbonates; Diabetes Mellitus, Type 2; Dialysis Solutions; Humans; H | 2011 |
Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
Topics: Administration, Inhalation; Albumins; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Drug Del | 2011 |
Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early | 2011 |
Increased lipolysis but diminished gene expression of lipases in subcutaneous adipose tissue of healthy young males with intrauterine growth retardation.
Topics: Adult; Bed Rest; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fetal Growth Retardation; | 2011 |
Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model.
Topics: Animals; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Diabetes Mellitus, Type 2; gamma-Aminobuty | 2012 |
Effect of percutaneous electrical muscle stimulation on postprandial hyperglycemia in type 2 diabetes.
Topics: Analysis of Variance; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Electric Stimulation; Hum | 2012 |
L(+) and D(-) lactate are increased in plasma and urine samples of type 2 diabetes as measured by a simultaneous quantification of L(+) and D(-) lactate by reversed-phase liquid chromatography tandem mass spectrometry.
Topics: Adult; Aged; Chromatography, Reverse-Phase; Diabetes Mellitus, Type 2; Female; Humans; Inflammatory | 2012 |
The gonadal hormone regulates the plasma lactate levels in type 2 diabetes treated with and without metformin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Estrogens; Fasting; Female; Glycated Hemoglob | 2012 |
Metformin therapy in patients with chronic kidney disease.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2012 |
Role of hyperglycemia-mediated erythrocyte redox state alteration in the development of diabetic retinopathy.
Topics: Blood Glucose; Blood Pressure; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopa | 2013 |
Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients.
Topics: Aged; Animals; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Hemodynamics; Humans; Ische | 2012 |
Metabolic master regulators: sharing information among multiple systems.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Insulin Resistance; Lactic A | 2012 |
Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Blood Glucose; Cohort Studies; Cross-Sectional Studies; Di | 2012 |
Metabolomic profilings of urine and serum from high fat-fed rats via 1H NMR spectroscopy and pattern recognition.
Topics: 3-Hydroxybutyric Acid; Animals; Choline; Citric Acid; Creatinine; Diabetes Mellitus, Type 2; Dietary | 2013 |
A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Synergism; Excipients; Exenatide; Gel | 2013 |
Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study.
Topics: Atherosclerosis; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; In | 2013 |
Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycogen; H | 2003 |
Lactic acidemia associated with metformin.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; L | 2003 |
Impairment of myocardial protection in type 2 diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Pressure; Chest Pain; Diabetes Mellitus, Type 2; Electro | 2003 |
Impaired oxidative phosphorylation in skeletal muscle of intrauterine growth-retarded rats.
Topics: Aconitate Hydratase; Adenosine Triphosphate; Animals; Blood Glucose; Blotting, Western; Citrate (si) | 2003 |
Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control.
Topics: Aged; Blood Glucose; Body Constitution; Body Mass Index; Diabetes Mellitus, Type 2; Female; Fluorode | 2003 |
[Metformin-associated lactic acidosis precipitated by acute renal failure].
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Blood Gas Analysis; Diabetes Mellitus, Type 2; Female; | 2003 |
[Metformin-associated lactic acidosis remains a serious complication of metformin therapy].
Topics: Acidosis, Lactic; Acute Kidney Injury; Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type | 2003 |
Effects of strength training on muscle lactate release and MCT1 and MCT4 content in healthy and type 2 diabetic humans.
Topics: Blood Glucose; Case-Control Studies; Cell Cycle Proteins; Diabetes Mellitus, Type 2; Glucose Clamp T | 2004 |
Metabolism of 13C-enriched D-fructose in hepatocytes from Goto-Kakizaki rats.
Topics: Alanine; Animals; Buffers; Carbon Isotopes; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Mode | 2004 |
Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Excipients; Glucagon | 2004 |
Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration.
Topics: Administration, Oral; Alanine; Animals; Arabinose; Blood Glucose; Chlorogenic Acid; Diabetes Mellitu | 2005 |
Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Area Under Curve; Blood Glucose; Chylomicrons; Diabetes Mellitus, Type 2; Die | 2005 |
Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats.
Topics: Animals; Carbon Isotopes; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids; Glucose; In Vit | 2005 |
Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; Fatty Acids; G | 2005 |
Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle.
Topics: Animals; Diabetes Mellitus, Type 2; Energy Metabolism; Enzyme Activation; Enzyme Inhibitors; Glycoge | 2005 |
Relationship between blood lactate concentration and substrate utilization during exercise in type 2 diabetic postmenopausal women.
Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Erythrocytes; Exercise; Female; Humans; Lactic Acid; M | 2005 |
Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.
Topics: Alanine; Blood Glucose; Carbon Dioxide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Femal | 2006 |
Contraindications can damage your health--is metformin a case in point?
Topics: Acidosis, Lactic; Aging; Contraindications; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypog | 2005 |
Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes.
Topics: Animals; Blood Glucose; Body Weight; Butyrates; Carbon Radioisotopes; Deoxyglucose; Diabetes Mellitu | 2006 |
Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose-Bisphosphatase; Gluconeogenesis | 2006 |
Relation between increased anaerobic glycolysis and visual acuity in long-standing type 2 diabetes mellitus without retinopathy.
Topics: Anaerobic Threshold; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Follow-Up | 2006 |
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
Topics: Alanine; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Eating; Female | 2006 |
The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gluc | 2006 |
Insulin resistance and the mitochondrial link. Lessons from cultured human myotubes.
Topics: 2,4-Dinitrophenol; Antimycin A; Case-Control Studies; Cells, Cultured; Diabetes Mellitus, Type 2; Gl | 2007 |
Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal function.
Topics: Acidosis, Lactic; Asia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2007 |
Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats.
Topics: Adiponectin; Animals; bcl-X Protein; Cardiovascular Agents; Coronary Vessels; Diabetes Mellitus, Exp | 2007 |
Berberine improves glucose metabolism through induction of glycolysis.
Topics: 3T3-L1 Cells; Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; AMP-Activated Protein Kin | 2008 |
The effect of short term lithium carbonate in Type II diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin; Lacta | 1983 |
Microdialysis assessment of adipose tissue metabolism in post-absorptive obese NIDDM subjects.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Female; Glycerol; Humans; Lactates; Lactic Acid; Male; Mi | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Fe | 1995 |
Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; | 1994 |
Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus.
Topics: Adult; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucose; Hu | 1994 |
Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications.
Topics: Adult; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 1994 |
Levels of lactic acid in normal Indians & its relation to food, glucose, cholesterol, raised blood urea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Child; Cholesterol; Diabetes Mellitus, Ty | 1993 |
Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin.
Topics: Adult; Diabetes Mellitus, Type 2; Erythrocytes; Glucose; Glycogen; Humans; Hyperglycemia; Lactates; | 1993 |
Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Glycogen; Glycolysis; | 1993 |
Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals.
Topics: Adult; Blood Glucose; Body Fluid Compartments; Diabetes Mellitus, Type 2; Forearm; Humans; Hyperglyc | 1996 |
Acute necrotizing pancreatitis, lactic acidosis and prolonged hypoglycemia in a hemodialysed patient--a logical but unfortunately fatal combination.
Topics: Acidosis, Lactic; Blood Gas Analysis; Blood Glucose; Diabetes Mellitus, Type 2; Fatal Outcome; Femal | 1996 |
McArdle's disease with non-insulin-dependent diabetes mellitus: the beneficial effects of hyperglycemia and hyperinsulinemia for exercise intolerance.
Topics: Biopsy; Blood Glucose; Cerebral Infarction; Creatine Kinase; Diabetes Mellitus, Type 2; Eating; Exer | 1996 |
Metabolic and endocrine effects of interleukin-1 in obese, diabetic Zucker fa/fa rats.
Topics: Animals; Blood Glucose; Cholesterol; Corticosterone; Diabetes Mellitus; Diabetes Mellitus, Type 2; D | 1996 |
Glucose metabolism and catecholamine responses during physical exercise in non-insulin-dependent diabetes.
Topics: Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Electrocardiography; Epinephrin | 1996 |
Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study.
Topics: Diabetes Mellitus, Type 2; Female; Gas Chromatography-Mass Spectrometry; Gluconeogenesis; Glucose; H | 1996 |
Ethanol impairs insulin-mediated glucose uptake by an indirect mechanism.
Topics: Adult; Deoxyglucose; Diabetes Mellitus, Type 2; Ethanol; Fatty Acids, Nonesterified; Fluorine Radioi | 1996 |
[The effect of metformin on lactate levels in type II diabetes].
Topics: Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agent | 1996 |
Lactic acidosis associated with Glucophage use in a man with normal renal and hepatic function.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Human | 1997 |
Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; F | 1997 |
Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands.
Topics: Adipose Tissue; Adult; Aged; Body Composition; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty A | 1998 |
The metabolic effects of pokeweed mitogen in mice.
Topics: Animals; B-Lymphocytes; Blood Glucose; Cell Line; Cytokines; Deoxyglucose; Diabetes Mellitus, Type 2 | 1998 |
Possible synergistic effect of metformin and enalapril on the development of hyperkaliemic lactic acidosis.
Topics: Acidosis; Aged; Antihypertensive Agents; Chlorides; Diabetes Mellitus, Type 2; Drug Synergism; Drug | 1997 |
Minimal influence of blood flow on interstitial glucose and lactate-normal and insulin-resistant muscle.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Insulin; Insulin Resistanc | 1998 |
Effects of the novel oral antidiabetic agent HQL-975 on glucose and lipid metabolism in diabetic db/db mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glycogen; Hypoglycemic Agents; Insul | 1998 |
Defect of an early event of glucose metabolism in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty (OLETF) rat, a non-insulin-dependent diabetes mellitus (NIDDM) model.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Glucose-6-Phosphate; Glycogen S | 1998 |
The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; C-Peptide; Calorimetry, Indirect; Chromatography, High Pressure Liquid; Diabetes Mell | 1998 |
Glucose metabolism in Goto-Kakizaki rat islets.
Topics: Acetates; Adenosine Triphosphate; Animals; Carbon Dioxide; Diabetes Mellitus, Type 2; Glucose; In Vi | 1998 |
Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluc | 1998 |
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Arteries; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty | 1998 |
Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia.
Topics: Adult; Alanine; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; Fe | 1998 |
Effects of starvation and diabetes on the metabolism of [2,3-13C]succinic acid dimethyl ester in rat hepatocytes.
Topics: Animals; Carbon Isotopes; Diabetes Mellitus, Type 2; Female; Glucose; Lactic Acid; Liver; Malates; R | 1999 |
Skin mini-erosion technique for monitoring metabolites in interstitial fluid: its feasibility demonstrated by OGTT results in diabetic and non-diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Extracellular Space; Female; | 1999 |
Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Food; Gluca | 1999 |
Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients.
Topics: Adult; Body Mass Index; Case-Control Studies; Dexamethasone; Diabetes Mellitus, Type 2; Female; Gluc | 1999 |
Noninvasive tracing of human liver metabolism: comparison of phenylacetate and apoB-100 to sample glutamine.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gl | 1999 |
Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Glucokinase; Glucose; Glycogen Synthase; Glycol | 1999 |
Ethnicity affects the postprandial regulation of glycogenolysis.
Topics: Adult; Asian People; Blood Glucose; Carbon Isotopes; Diabetes Mellitus, Type 2; Energy Metabolism; G | 1999 |
Lactic acidosis in metformin therapy.
Topics: Acidosis, Lactic; Adult; Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactic Acid; | 1999 |
Activation of glycogen synthase a in hepatocytes exposed to alpha-D-glucose pentaacetate.
Topics: Animals; Cell Separation; Diabetes Mellitus, Type 2; Enzyme Activation; Glucose; Glycogen Synthase; | 2000 |
Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.
Topics: Animals; Arabinose; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glucagon; G | 2000 |
Estimations of muscle interstitial insulin, glucose, and lactate in type 2 diabetic subjects.
Topics: Adult; Arteries; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Ext | 2000 |
Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa.
Topics: Adipose Tissue; Adult; Black People; Body Composition; C-Peptide; Diabetes Mellitus; Diabetes Mellit | 2001 |
Increased lactate release per fat cell in normoglycemic first-degree relatives of individuals with type 2 diabetes.
Topics: Abdomen; Adipocytes; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Clamp | 2001 |
[Novel methods in diabetes mellitus diagnosis].
Topics: Cadaver; Coma; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycemia; | 2001 |
Metabolism of D-[3-3H]glucose, D-[5-3H]glucose, D-[U-14C]glucose, D-[1-14C]glucose and D-[6-14C]glucose in pancreatic islets in an animal model of type-2 diabetes.
Topics: Animals; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Glycolysi | 2002 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Topics: Animals; Cardiotonic Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2002 |
Evidence against glycogen cycling of gluconeogenic substrates in various liver preparations.
Topics: Animals; Arabinose; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fema | 2002 |
Cardiac carbohydrate metabolism in Zucker diabetic fatty rats.
Topics: Animals; Carbohydrate Metabolism; Carbon Isotopes; Diabetes Mellitus, Type 2; Fatty Acids; Glucose; | 2002 |
Fluorimetric assay of D-lactate.
Topics: Calibration; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enzyme Stability; Fluorometry; Hu | 1992 |
[Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + fenformin lowers the lacticemia levels in type-2 diabetics (NIDDM)].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Female; | 1992 |
Postprandial thermogenesis at rest and postexercise before and after physical training in lean, obese, and mildly diabetic men.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Temperature Regulation; Diabetes Mellitus; Diabetes | 1992 |
Relationships of obesity indices to serum insulin and lipoproteins in relatives of black patients with noninsulin-dependent diabetes mellitus (NIDDM).
Topics: Adipose Tissue; Administration, Oral; Adult; Anthropometry; Black People; Blood Glucose; Body Mass I | 1991 |
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Topics: Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glycogen Synth | 1991 |
No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Ethanol; Fatty Acids, Nonesterified; Female; Glucone | 1991 |
Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Glipizide; Glucose; Humans; Injections, Intraveno | 1991 |
Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine Transaminase; Carnitine O-Palmitoyltransferase; Cholesterol; D | 1991 |
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; Female; Glucose; | 1991 |
Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients.
Topics: Alanine; Blood Glucose; Butyrates; Butyric Acid; Circadian Rhythm; Diabetes Mellitus, Type 2; Glycer | 1990 |
[Effect of biguanides on the indicators of thrombelastography and the level of lactic acid in diabetes mellitus].
Topics: Adolescent; Adult; Aged; Biguanides; Blood Coagulation; Diabetes Mellitus, Type 1; Diabetes Mellitus | 1990 |
Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake.
Topics: Adult; Diabetes Mellitus, Type 2; Glucose; Glycogen Synthase; Humans; Lactates; Lactic Acid; Lipid M | 1990 |
To what extent can metabolism be 'normalized' in insulin-dependent diabetes?
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Evaluation Studies as Topi | 1990 |
Effect of insulin on glucose utilization in epitrochlearis muscle of rats with streptozocin-induced NIDDM.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 1990 |
Biguanide-induced lactic acidosis.
Topics: Acidosis, Lactic; Adult; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Lactates; Lactic Acid | 1990 |
Lactate generation following glucose ingestion: relation to obesity, carbohydrate tolerance and insulin sensitivity.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Carbohy | 1990 |
Gastrointestinal and metabolic effects of amylase inhibition in diabetics.
Topics: Aged; Amylases; Blood Glucose; Breath Tests; C-Peptide; Diabetes Mellitus, Type 2; Diarrhea; Dietary | 1988 |
The relationship of plasma acetate with glucose and other blood intermediary metabolites in non-diabetic and diabetic subjects.
Topics: Acetates; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Fatty | 1989 |
Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; F | 1989 |
Direct evidence for a stimulatory effect of hyperglycemia per se on peripheral glucose disposal in type II diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Female; Hemoglobin A; H | 1986 |
Chlorpropamide raises fructose-2,6-bisphosphate concentration and inhibits gluconeogenesis in isolated rat hepatocytes.
Topics: Animals; Chlorpropamide; Cyclic AMP; Diabetes Mellitus, Type 2; Fructosediphosphates; Gluconeogenesi | 1986 |
Abnormal glucoregulation during exercise in type II (non-insulin-dependent) diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Growth Hormone; H | 1987 |
Potentiation of glucose-stimulated insulin release by tolazamide and paradoxical absence of glucose facilitation (Staub effect) in non-insulin-dependent diabetes.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Secretion; Lactates; Lactic Acid; Stimu | 1986 |
Mechanism of metformin action in non-insulin-dependent diabetes.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Gl | 1987 |
[Circadian profiles of lactic and pyruvic acid in diabetic patients treated with biguanides and sulfonylureas].
Topics: Aged; Biguanides; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Diet, Diabetic; Humans | 1986 |
Insulin infusion (GIK) in the treatment of type 2 (non-insulin dependent) diabetes during the perioperative period.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose | 1986 |
[Alteration of blood lactic acid levels in biguanide therapy in diabetics].
Topics: Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Lactates; Lacti | 1985 |